

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02048

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB) 9 February 1995 see claims and figures	1-26
Y	US 5 302 509 A (CHEESEMAN PETER C) 12 April 1994 see the whole document	1-26
A	WO 96 32504 A (UNIV BOSTON) 17 October 1996	1-26
A	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 see the whole document	1-26



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/GB 98/02048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504160 A	09-02-1995	AT 159767 T AU 695349 B AU 7269194 A CA 2168010 A CN 1131440 A DE 69406544 D DE 69406544 T DK 711362 T EP 0711362 A EP 0778280 A ES 2108479 T FI 960403 A HU 73802 A JP 9501830 T NO 960370 A US 5770367 A	15-11-1997 13-08-1998 28-02-1995 09-02-1995 18-09-1996 04-12-1997 26-02-1998 22-12-1997 15-05-1996 11-06-1997 16-12-1997 29-01-1996 30-09-1996 25-02-1997 28-03-1996 23-06-1998
US 5302509 A	12-04-1994	NONE	
WO 9632504 A	17-10-1996	AU 5544696 A CA 2218188 A EP 0830460 A	30-10-1996 17-10-1996 25-03-1998
WO 9633205 A	24-10-1996	US 5750341 A AU 5549096 A CA 2218017 A EP 0871646 A	12-05-1998 07-11-1996 24-10-1996 21-10-1998
WO 9727331 A	31-07-1997	AU 2247397 A EP 0868535 A	20-08-1997 07-10-1998

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

DANIELS, Jeffrey, Nicholas
Page White & Farrer
54 Doughty Street
London WC1N 2LS
ROYAUME-UNIDate of mailing (day/month/year)
21 April 1999 (21.04.99)Applicant's or agent's file reference
88208/JND

IMPORTANT NOTIFICATION

International application No.
PCT/GB98/02048International filing date (day/month/year)
13 July 1998 (13.07.98)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

BRAX GENOMICS LIMITED
13 Station Road
Cambridge CB1 2JB
United KingdomState of Nationality
GBState of Residence
GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

BRAX GROUP LIMITED
13 Station Road
Cambridge CB1 2JB
United KingdomState of Nationality
GBState of Residence
GB

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Yolaine CUSSAC

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

14 April 1999 (14.04.99)

International application No.

PCT/GB98/02048

Applicant's or agent's file reference

88208/JND

International filing date (day/month/year)

13 July 1998 (13.07.98)

Priority date (day/month/year)

11 July 1997 (11.07.97)

Applicant

SCHMIDT, Günter et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

05 February 1999 (05.02.99)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

C. Carrié

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 88208/JND	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/GB 98/ 02048	International filing date (<i>day/month/year</i>) 13/07/1998	(Earliest) Priority Date (<i>day/month/year</i>) 11/07/1997
Applicant BRAX GENOMICS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ **Certain claims were found unsearchable** (see Box I).

2. ☐ **Unity of invention is lacking** (see Box II).

3. ☐ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the **title**, ☒ the text is approved as submitted by the applicant

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is:

Figure No. 4 ☐ as suggested by the applicant.

☐ None of the figures.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02048

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y ✓	W0 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB) 9 February 1995 see claims and figures ---	1-26
Y ✓	US 5 302 509 A (CHEESEMAN PETER C) 12 April 1994 see the whole document ---	1-26
A ✓	W0 96 32504 A (UNIV BOSTON) 17 October 1996 ---	1-26
A ✓	W0 96 33205 A (SPECTRAGEN INC) 24 October 1996 see the whole document ---	1-26
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X ✓	WO 97 27331 A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 see whole document, esp examples and claims -----	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504160 A	09-02-1995	AT 159767 T AU 695349 B AU 7269194 A CA 2168010 A CN 1131440 A DE 69406544 D DE 69406544 T DK 711362 T EP 0711362 A EP 0778280 A ES 2108479 T FI 960403 A HU 73802 A JP 9501830 T NO 960370 A US 5770367 A	15-11-1997 13-08-1998 28-02-1995 09-02-1995 18-09-1996 04-12-1997 26-02-1998 22-12-1997 15-05-1996 11-06-1997 16-12-1997 29-01-1996 30-09-1996 25-02-1997 28-03-1996 23-06-1998
US 5302509 A	12-04-1994	NONE	
WO 9632504 A	17-10-1996	AU 5544696 A CA 2218188 A EP 0830460 A	30-10-1996 17-10-1996 25-03-1998
WO 9633205 A	24-10-1996	US 5750341 A AU 5549096 A CA 2218017 A EP 0871646 A	12-05-1998 07-11-1996 24-10-1996 21-10-1998
WO 9727331 A	31-07-1997	AU 2247397 A EP 0868535 A	20-08-1997 07-10-1998

PATENT COOPERATION TREATY

RECEIVED

14 JUL 1999

Ans'd.....

PCT

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

DANIELS, J.
PAGE WHITE & FARRER
54 Doughty Street
LONDON WC1N 2LS
GRANDE BRETAGNE

WRITTEN OPINION

(PCT Rule 66)

Date of mailing
(day/month/year) **12.07.99**

Applicant's or agent's file reference
88208/JND

REPLY DUE **within 3 month(s)**
from the above date of mailing

International application No.
PCT/GB98/02048

International filing date (day/month/year)
13/07/1998

Priority date (day/month/year)
11/07/1997

International Patent Classification (IPC) or both national classification and IPC
C12Q1/68

Applicant

BRAX GROUP LIMITED et al

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain document cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).


How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3.. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **11/11/1999**.

Name and mailing address of the international preliminary examining authority:

 European Patent Office
D-80298 Munich
Tel. (+49-89) 2399-0 Tx: 523656 epmu d
Fax: (+49-89) 2399-4465

Authorized officer / Examiner

GONCALVES M L F C

Formalities officer (incl. extension of time limits)

Danti, B

Telephone No. (+49-89) 2399 8161



I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

Description, pages:

1-51 as originally filed

Claims, No.:

1-26 as originally filed

Drawings, sheets:

1/14-14/14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	1, 14-26 (no) 2-13(yes)
Inventive step (IS)	Claims	1-26 (no)
Industrial applicability (IA)	Claims	1-26 (yes)

2. Citations and explanations

see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Section V

1. Reference is made to the following documents:

D1: WO-A-95 04160

D2: WO-A-96 32504

D3: WO-A-98 15652

D4: WO-A-97 27331

2. The subject-matter of claim 1 is a method for characterising DNA, comprising steps (i) to (iv). Methods for characterising DNA comprising the same method steps as the method of claim 1 appear to be disclosed in the following prior art documents:

D1 describes a reagent comprising: (i) an analyte moiety containing two analyte residues; and linked to (ii) a tag moiety containing one reporter group adapted for detection by mass spectrometry; the reporter group designates an analyte residue, and the reporter group at each portion of the tag moiety is chosen to designate an analyte residue at a defined position on the analyte. Also disclosed in D1 are a library of reagents each comprising a different analyte moiety and an assay method comprising: (i) providing a target substance; (ii) incubating the target substance with the library of reagents under conditions to cause binding of one reagent to the target substance; (iii) removing un-bound reagents; (iv) recovering the tag moieties of each bound reagent; and (v) analysing the tag moieties as an indication of the nature of the analyte moieties bound to the target substance; etc. The reagents and libraries can be used for nucleic acid sequencing and for detecting particular analytes, e.g. for drug screening. The method of D1 has good sensitivity and resolution. The mass labelling combines the advantages of radioactivity and fluorescence (see claims). D2 describes a method of sequencing or detecting a target nucleic acid, which comprises: (1) providing a set of nucleic acid fragments containing a sequence corresponding to a target sequence (optionally by fragmenting the target sequence), and hybridizing these to an array (optionally attached to a solid support when the fragments are obtained by fragmenting the target sequence) of nucleic acid probes (optionally mass modified), comprising a double and single stranded portion containing a variable sequence to form a target nucleic acid array, then determining the sequence of the target nucleic acid by: (a) determining molecular weights

for several nucleic acids of the target array; (b) extending and mass modifying a strand of the probe using the hybridised fragment as a template, and determining molecular weights for several mass modified extended nucleic acids by mass spectrometry; (c) extending a strand of the mass modified probes using the hybridised fragments as templates, and determining molecular weights for a plurality of extended mass modified strands; (d) extending a strand of the probe enzymatically using the hybridised fragment as a template to create an extended nucleic acid, removing alkali cations from the extended nucleic acid and determining mol. weight. for several protonated and extended nucleic acids by mass spectrometry; or (e) extending a strand of the probe using the hybridised fragment as a template and determining mol. weight. for several nucleic acids of the target array; (2) providing a set of partially single stranded nucleic acid fragments containing a target sequence, and hybridizing the single stranded portions of the fragments to single stranded portions of a set of partially double stranded nucleic acid probes to form a set of complexes (optionally containing a variable sequence within the single stranded region), determining the sequence of the target nucleic acid by ligating a single strand of the fragment to an adjacent single strand of the probe, and: (a) extending the unligated strand of the complex by strand-displacement polymerisation using the ligated strand as a template; or (b) extending the unligated strand of the complex by strand displacement polymerisation using the ligated strand as a template, mass modifying the extended strand and determining the molecular weights of the extended strands by mass spectrometry; or (3) providing a set of nucleic acids complementary or homogenous to a sequence of the target, hybridizing the set to an array of single stranded nucleic acid probes, comprising a constant sequence and a determinable variable sequence and identifying the target sequence by determining molecular weights of hybridised nucleic acids. The methods are useful in the identification, analysis and diagnosis of diseases and disorders, and in determining relationships between organisms. The methods of this document, based on positional sequencing by hybridisation (PSBH), with their ability to bind and discriminate between different sequences with large or small arrays of probes is well suited to mass spectrometric analysis, unlike conventional methods based on base by base sequence identification (see abstract and

claims).

From the above analysis of the prior art, the subject-matter of claim 1 does not appear to be novel (Article 33(2) PCT).

3. The additional features added by the dependent claims 14-20 to the method of claim 1 ^{is!} refer to standard options in the art and thus cannot contribute to the novelty of the claimed subject-matter (Article 33(2) PCT). The additional features introduced by the dependent claims 2-13 to the method of claim 1 are not explicitly disclosed in the prior art documents and therefore are novel. Because these additional features do not appear to result in any unexpected effects whatsoever, they can not contribute to the inventiveness of the subject-matter of claim 1 (Article 33(3) PCT).
4. The above comments also apply to the subject-matter of claims 22, 23 and 24 (referring to preferred embodiments of the method of claim 1) and to claims 25 and 26 (referring to the use of probes or oligonucleotide in the claimed methods) and to the claims dependent thereon.

Section VI

1. The document WO-A-98 15652, from the same applicants, discloses the nucleic acid sequencing by adaptor ligation. The method for sequencing nucleic acids comprises:
- (a) obtaining a target nucleic acid population comprising nucleic acid fragments in which each fragment is present in a unique amount and bears a sticky end sequence of predetermined length and unknown sequence;
 - (b) protecting the other end of each fragment, and
 - (c) sequencing each of the fragments by:
 - (i) contacting the fragments with an array of adaptor oligonucleotides (ONs) under hybridisation conditions, each adaptor ON bearing a label, a sequencing enzyme recognition site, and a known unique base sequence of the same predetermined length as the sticky base sequence, the array containing all possible base sequences of that predetermined length, removing any unhybridised adaptor ON and recording the quantity of any hybridised adaptor ON by detection of the label, then repeating the cycle, until all of the adaptors in the array have been tested;
 - (ii) contacting the hybridised adaptor ONs with a sequencing enzyme

which binds to the recognition site and cuts the fragment to expose a new sticky end sequence which is contiguous with or overlaps the previous sticky end sequence;

- (iii) repeating steps (i) and (ii) for a number of times and determining the sequence of the fragment by comparing the quantities recorded for each sticky end sequence. The method can be used for the simultaneous sequencing of a heterogeneous population of nucleic acid fragments without spatially resolving them (see abstract and claims).

WO-A-97 27331 from the Darwin Molecular Corp., describes a method for determining the sequence of a nucleic acid molecule which comprises: (a) generating tagged nucleic acid fragments which are complementary to a selected target nucleic acid, where a tag is correlative with a particular nucleotide and detectable by non-fluorescent spectrometry or potentiometry; (b) separating the tagged fragments by sequential length; (c) cleaving the tags from the tagged fragments; and (d) detecting the tags by non-fluorescent spectrometry or potentiometry, and from this determining the sequence.

Also disclosed in this document are compounds of the formula Tms-L-X and where: Tms = an organic group detectable by mass spectrometry comprises carbon, at least one of H and F, and optional atoms selected from O, N, S, P and I; L = an organic group which allows a Tms-containing moiety to be cleaved from the remainder of the compound, where the Tms-containing moiety comprises a functional group which supports a single ionised charge state when the compound is subjected to mass spectrometry and is selected from tertiary amine, quaternary amine and organic acid; and X = a functional group selected from hydroxyl, amino, thio, carboxylic acid, haloalkyl and derivatives of these which activate or inhibit the activity of the group toward coupling with other moieties, or is a nucleic acid fragment attached to L at other than the 3' end of the fragment; provided that the compound is not bonded to a solid support through X nor has a mass of less than 250 Daltons (see abstract and claims).

The methods and compounds described may be used e.g. for determining the sequences of nucleic acid molecules. They may be used for determination of multiple nucleic acid sequences simultaneously. The methods and compounds of WO-A-97 27331 allow sequencing to be

performed with enhanced speed and sensitivity.

These documents, therefore, would appear to disclose the subject-matter of claims 1, 21, 22, 23 and 24 of the present application.

However, it is assumed that the priority date of the present application is validly claimed. The present priority date of 11/7/97 is, namely, before the publication dates of 16/4/98(WO-A-98 15652) and 31/7/97(WO-A-97 27331).

Section VII

1. In order for the application to be self-contained (see further the PCT Guidelines, C-II, 4.17), the references to patent applications numbers should be changed to publication numbers throughout the description.

Section VIII

1. Although the groups of claims 1, 21, 22, 23 and 24 and 25, 26 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and/or in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it difficult, if not impossible, to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.

Hence, claims 1, 21, 22, 23, 24 and 25, 26 do not meet the requirements of Article 6 PCT.

In order to overcome this objection, it would appear appropriate to file an amended set of claims defining the relevant subject-matter in terms of a single independent claim in each category followed by dependent claims covering features which are merely optional (Rule 6.4 PCT).

2. The applicant attention is called to the fact that there appear to be more international applications from the same applicant (for example PCT/US 98/02044) designating the same states and the claims of those applications have the same priority date and relate to the same invention, thus the applicant may be required in the national phase to choose which

**WRITTEN OPINION
SEPARATE SHEET**

International application No. PCT/GB98/02048

one of those applications he wishes to proceed to grant (see further the PCT guidelines, C-IV, 6.3).



PATENT COOPERATION TREATY

PCT

REC'D	25 OCT 1999
WIPO	PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 88208/JND		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB98/02048	International filing date (day/month/year) 13/07/1998	Priority date (day/month/year) 11/07/1997	
International Patent Classification (IPC) or national classification and IPC C12Q1/68			
Applicant BRAX GROUP LIMITED et al			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none">I <input checked="" type="checkbox"/> Basis of the reportII <input type="checkbox"/> PriorityIII <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicabilityIV <input type="checkbox"/> Lack of unity of inventionV <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statementVI <input checked="" type="checkbox"/> Certain documents citedVII <input checked="" type="checkbox"/> Certain defects in the international applicationVIII <input checked="" type="checkbox"/> Certain observations on the international application			
Date of submission of the demand 05/02/1999		Date of completion of this report 19. 10. 99	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer GONCALVES M L F C Telephone No. +49 89 2399 8127 	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/02048

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-51 as originally filed

Claims, No.:

1-26 as originally filed

Drawings, sheets:

1/14-14/14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/02048

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-26
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-26
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations

see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

Section V

1. The following documents are considered to form the most relevant prior art:

D1: WO-A-95 04160

D2: WO-A-98 15652

D3: WO-A-97 27331

2. The subject-matter of claim 1 is a method for characterising DNA, comprising steps (i) to (iv). Methods for characterising DNA comprising the same method steps as the method of claim 1 appear to be disclosed in the following prior art document:

D1 describes a reagent comprising: (i) an analyte moiety containing two analyte residues; and linked to (ii) a tag moiety containing one reporter group adapted for detection by mass spectrometry; the reporter group designates an analyte residue, and the reporter group at each portion of the tag moiety is chosen to designate an analyte residue at a defined position on the analyte. Also disclosed in D1 are a library of reagents each comprising a different analyte moiety and an assay method comprising: (i) providing a target substance; (ii) incubating the target substance with the library of reagents under conditions to cause binding of one reagent to the target substance; (iii) removing un-bound reagents; (iv) recovering the tag moieties of each bound reagent; and (v) analysing **the recovered tag moieties** as an indication of the nature of the analyte moieties bound to the target substance; etc. **The tag moiety is suitable for analysis by mass spectrometry after cleavage from the reagent** (see page 3, lines 6-9). The reagents and libraries can be used for nucleic acid sequencing and for detecting particular analytes, e.g. for drug screening. The method of D1 has good sensitivity and resolution. The mass labelling combines the advantages of radioactivity and fluorescence (see claims).

From the above analysis of D1, the subject-matter of claim 1 distinguishes itself from the method of this document by including the step of "separating the fragments on the basis of their length" and is therefore novel (Article 33(2) PCT). Because the distinguishing feature does not appear to result in any unexpected technical effects whatsoever (on the contrary this is an additional step to the method of D1), the subject-matter of claim 1 is not considered to be based on an inventive concept (Article 33(3) PCT).

3. The additional features added by the dependent claims 14-20 to the method of claim 1 refer to standard options in the art and thus cannot contribute to the inventiveness of the claimed subject-matter (Article 33(3) PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

The additional features introduced by the dependent claims 2-13 to the method of claim 1 are not explicitly disclosed in the prior art documents and therefore are novel. Because these additional features do not appear to result in any unexpected effects whatsoever, they can not contribute to the inventiveness of the subject-matter of claim 1 (Article 33(3) PCT).

4. The above comments also apply to the subject-matter of claims 21, 22, 23 and 24 (referring to preferred embodiments of the method of claim 1) and to claims 25 and 26 (referring to the use of probes or oligonucleotide in the claimed methods) and to the claims dependent thereon (Article 33(3) PCT).

Section VI

1. The document D2, from the same applicants, discloses the nucleic acid sequencing by adaptor ligation. The method for sequencing nucleic acids comprises:
- (a) obtaining a target nucleic acid population comprising nucleic acid fragments in which each fragment is present in a unique amount and bears a sticky end sequence of predetermined length and unknown sequence;
 - (b) protecting the other end of each fragment, and
 - (c) sequencing each of the fragments by:
 - (i) contacting the fragments with an array of adaptor oligonucleotides (ONs) under hybridisation conditions, each adaptor ON bearing a label, a sequencing enzyme recognition site, and a known unique base sequence of the same predetermined length as the sticky base sequence, the array containing all possible base sequences of that predetermined length, removing any unhybridised adaptor ON and recording the quantity of any hybridised adaptor ON by detection of the label, then repeating the cycle, until all of the adaptors in the array have been tested;
 - (ii) contacting the hybridised adaptor ONs with a sequencing enzyme which binds to the recognition site and cuts the fragment to expose a new sticky end sequence which is contiguous with or overlaps the previous sticky end sequence;
 - (iii) repeating steps (i) and (ii) for a number of times and determining the sequence of the fragment by comparing the quantities recorded for each sticky end sequence.
- The method can be used for the simultaneous sequencing of a heterogeneous population of nucleic acid fragments without spatially resolving them (see abstract and claims).
- D3 from the Darwin Molecular Corp., describes a method for determining the sequence of a nucleic acid molecule which comprises: (a) generating tagged nucleic acid fragments which are complementary to a selected target nucleic acid, where a

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

tag is correlative with a particular nucleotide and detectable by non-fluorescent spectrometry or potentiometry; (b) separating the tagged fragments by sequential length; (c) cleaving the tags from the tagged fragments; and (d) detecting the tags by non-fluorescent spectrometry or potentiometry, and from this determining the sequence.

Also disclosed in this document are compounds of the formula Tms-L-X and where: Tms = an organic group detectable by mass spectrometry comprises carbon, at least one of H and F, and optional atoms selected from O, N, S, P and I; L = an organic group which allows a Tms-containing moiety to be cleaved from the remainder of the compound, where the Tms-containing moiety comprises a functional group which supports a single ionised charge state when the compound is subjected to mass spectrometry and is selected from tertiary amine, quaternary amine and organic acid; and X= a functional group selected from hydroxyl, amino, thio, carboxylic acid, haloalkyl and derivatives of these which activate or inhibit the activity of the group toward coupling with other moieties, or is a nucleic acid fragment attached to L at other than the 3' end of the fragment; provided that the compound is not bonded to a solid support through X nor has a mass of less than 250 Daltons (see abstract and claims).

The methods and compounds described may be used e.g. for determining the sequences of nucleic acid molecules. They may be used for determination of multiple nucleic acid sequences simultaneously. The methods and compounds of WO-A-97 27331 allow sequencing to be performed with enhanced speed and sensitivity.

These documents, therefore, would appear to disclose the subject-matter of claims 1, 21, 22, 23 and 24 of the present application.

However, it is assumed that the priority date of the present application is validly claimed. The present priority date of 11/7/97 is, namely, before the publication dates of 16/4/98(WO-A-98 15652) and 31/7/97(WO-A-97 27331). Documents D2 and D3 could become relevant for the assessment of novelty in a future regional phase before the EPO.

Section VII

1. In order for the application to be self-contained (see further the PCT Guidelines, C-II, 4.17), the references to patent applications numbers should have been changed to publication numbers throughout the description.

Section VIII

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

1. Claims 1, 21, 22, 23 , 24 and 25, 26 do not meet the requirements of Article 6 PCT. Because claims 21, 22, 23 and 24 comprise all the features of claim 1, these claims should have been formulated as claims dependent on the latter (Rule 6.4 PCT).
2. The applicant attention is called to the fact that there appear to be more international applications from the same applicant (for example PCT/US 98/02044) designating the same states and the claims of those applications have the same priority date and relate to the same invention, thus the applicant may be required in the national phase to choose which one of those applications he wishes to proceed to grant (see further the PCT guidelines, C-IV, 6.3).

PATENT COOPERATION TREATY

✓

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
PAGE WHITE & FARRER
Attn. DANIELS, J.
54 Doughty Street
LONDON WC1N 2LS
UNITED KINGDOM

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

RECEIVED
- 2 NOV 1998

Applicant's or agent's file reference 88268/JND 88022	Date of mailing (day/month/year) 29/10/1998
International application No. PCT/GB 98/02048	International filing date (day/month/year) 13/07/1998*
Applicant BRAX GENOMICS LIMITED et al.	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority _____ European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, _____ Fax: (+31-70) 340-3016	Authorized officer Deborah Grandis
--	--

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]: ...
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 88208/JND	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 98/02048	International filing date (day/month/year) 13/07/1998	(Earliest) Priority Date (day/month/year) 11/07/1997
Applicant BRAX GENOMICS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☐ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application.

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. 4 ☐ as suggested by the applicant.

☐ None of the figures.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02048

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB) 9 February 1995 see claims and figures ---	1-26
Y	US 5 302 509 A (CHEESEMAN PETER C) 12 April 1994 see the whole document ---	1-26
A	WO 96 32504 A (UNIV BOSTON) 17 October 1996 ---	1-26
A	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 see the whole document ---	1-26
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 98/02048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 97 27331 A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 see whole document, esp examples and claims -----</p>	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02048

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9504160	A	09-02-1995	AT 159767 T AU 695349 B AU 7269194 A CA 2168010 A CN 1131440 A DE 69406544 D DE 69406544 T DK 711362 T EP 0711362 A EP 0778280 A ES 2108479 T FI 960403 A HU 73802 A JP 9501830 T NO 960370 A US 5770367 A	15-11-1997 13-08-1998 28-02-1995 09-02-1995 18-09-1996 04-12-1997 26-02-1998 22-12-1997 15-05-1996 11-06-1997 16-12-1997 29-01-1996 30-09-1996 25-02-1997 28-03-1996 23-06-1998
US 5302509	A	12-04-1994	NONE	
WO 9632504	A	17-10-1996	AU 5544696 A CA 2218188 A EP 0830460 A	30-10-1996 17-10-1996 25-03-1998
WO 9633205	A	24-10-1996	US 5750341 A AU 5549096 A CA 2218017 A EP 0871646 A	12-05-1998 07-11-1996 24-10-1996 21-10-1998
WO 9727331	A	31-07-1997	AU 2247397 A EP 0868535 A	20-08-1997 07-10-1998

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 88208/JND	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 98/02048	International filing date (day/month/year) 13/07/1998	(Earliest) Priority Date (day/month/year) 11/07/1997
Applicant BRAX GENOMICS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application.

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. 4 ☐ as suggested by the applicant.

☐ None of the figures.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02048

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB) 9 February 1995 see claims and figures	1-26
Y	US 5 302 509 A (CHEESEMAN PETER C) 12 April 1994 see the whole document	1-26
A	WO 96 32504 A (UNIV BOSTON) 17 October 1996	1-26
A	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 see the whole document	1-26
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No

CT/GB 98/02048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 27331 [✓] A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 see whole document, esp examples and claims -----	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02048

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9504160	A	09-02-1995	AT	159767 T	15-11-1997
			AU	695349 B	13-08-1998
			AU	7269194 A	28-02-1995
			CA	2168010 A	09-02-1995
			CN	1131440 A	18-09-1996
			DE	69406544 D	04-12-1997
			DE	69406544 T	26-02-1998
			DK	711362 T	22-12-1997
			EP	0711362 A	15-05-1996
			EP	0778280 A	11-06-1997
			ES	2108479 T	16-12-1997
			FI	960403 A	29-01-1996
			HU	73802 A	30-09-1996
			JP	9501830 T	25-02-1997
			NO	960370 A	28-03-1996
			US	5770367 A	23-06-1998

US 5302509	A	12-04-1994	NONE		

WO 9632504	A	17-10-1996	AU	5544696 A	30-10-1996
			CA	2218188 A	17-10-1996
			EP	0830460 A	25-03-1998

WO 9633205	A	24-10-1996	US	5750341 A	12-05-1998
			AU	5549096 A	07-11-1996
			CA	2218017 A	24-10-1996
			EP	0871646 A	21-10-1998

WO 9727331	A	31-07-1997	AU	2247397 A	20-08-1997
			EP	0868535 A	07-10-1998

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

DANIELS, J.
PAGE WHITE & FARRER
54 Doughty Street
LONDON WC1N 2LS
GRANDE BRETAGNE

RECEIVED

22 OCT 1999

Ans'd

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year)

19. 10. 99

Applicant's or agent's file reference
88208/JND

IMPORTANT NOTIFICATION

International application No.
PCT/GB98/02048

International filing date (day/month/year)
13/07/1998

Priority date (day/month/year)
11/07/1997

Applicant

BRAX GROUP LIMITED et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Houyez-Stevens, M

Tel. +49 89 2399-8163



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 88208/JND		FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB98/02048	International filing date (day/month/year) 13/07/1998	Priority date (day/month/year) 11/07/1997	
International Patent Classification (IPC) or national classification and IPC C12Q1/68			
Applicant BRAX GROUP LIMITED et al			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 05/02/1999	Date of completion of this report 19. 10. 99
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer GONCALVES M L F C Telephone No. +49 89 2399 8127



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/02048

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-51 as originally filed

Claims, No.:

1-26 as originally filed

Drawings, sheets:

1/14-14/14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/02048

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-26
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-26
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations

see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

Section V

1. The following documents are considered to form the most relevant prior art:

D1: WO-A-95 04160

D2: WO-A-98 15652

D3: WO-A-97 27331

2. The subject-matter of claim 1 is a method for characterising DNA, comprising steps (i) to (iv). Methods for characterising DNA comprising the same method steps as the method of claim 1 appear to be disclosed in the following prior art document:

D1 describes a reagent comprising: (i) an analyte moiety containing two analyte residues; and linked to (ii) a tag moiety containing one reporter group adapted for detection by mass spectrometry; the reporter group designates an analyte residue, and the reporter group at each portion of the tag moiety is chosen to designate an analyte residue at a defined position on the analyte. Also disclosed in D1 are a library of reagents each comprising a different analyte moiety and an assay method comprising: (i) providing a target substance; (ii) incubating the target substance with the library of reagents under conditions to cause binding of one reagent to the target substance; (iii) removing un-bound reagents; (iv) recovering the tag moieties of each bound reagent; and (v) analysing **the recovered tag moieties** as an indication of the nature of the analyte moieties bound to the target substance; etc. **The tag moiety is suitable for analysis by mass spectrometry after cleavage from the reagent** (see page 3, lines 6-9). The reagents and libraries can be used for nucleic acid sequencing and for detecting particular analytes, e.g. for drug screening. The method of D1 has good sensitivity and resolution. The mass labelling combines the advantages of radioactivity and fluorescence (see claims).

From the above analysis of D1, the subject-matter of claim 1 distinguishes itself from the method of this document by including the step of "separating the fragments on the basis of their length" and is therefore novel (Article 33(2) PCT). Because the distinguishing feature does not appear to result in any unexpected technical effects whatsoever (on the contrary this is an additional step to the method of D1), the subject-matter of claim 1 is not considered to be based on an inventive concept (Article 33(3) PCT).

3. The additional features added by the dependent claims 14-20 to the method of claim 1 refer to standard options in the art and thus cannot contribute to the inventiveness of the claimed subject-matter (Article 33(3) PCT).

The additional features introduced by the dependent claims 2-13 to the method of claim 1 are not explicitly disclosed in the prior art documents and therefore are novel. Because these additional features do not appear to result in any unexpected effects whatsoever, they can not contribute to the inventiveness of the subject-matter of claim 1 (Article 33(3) PCT).

4. The above comments also apply to the subject-matter of claims 21, 22, 23 and 24 (referring to preferred embodiments of the method of claim 1) and to claims 25 and 26 (referring to the use of probes or oligonucleotide in the claimed methods) and to the claims dependent thereon (Article 33(3) PCT). - ... *

Section VI

1. The document D2, from the same applicants, discloses the nucleic acid sequencing by adaptor ligation. The method for sequencing nucleic acids comprises:
- (a) obtaining a target nucleic acid population comprising nucleic acid fragments in which each fragment is present in a unique amount and bears a sticky end sequence of predetermined length and unknown sequence;
 - (b) protecting the other end of each fragment, and
 - (c) sequencing each of the fragments by:
 - (i) contacting the fragments with an array of adaptor oligonucleotides (ONs) under hybridisation conditions, each adaptor ON bearing a label, a sequencing enzyme recognition site, and a known unique base sequence of the same predetermined length as the sticky base sequence, the array containing all possible base sequences of that predetermined length, removing any unhybridised adaptor ON and recording the quantity of any hybridised adaptor ON by detection of the label, then repeating the cycle, until all of the adaptors in the array have been tested;
 - (ii) contacting the hybridised adaptor ONs with a sequencing enzyme which binds to the recognition site and cuts the fragment to expose a new sticky end sequence which is contiguous with or overlaps the previous sticky end sequence;
 - (iii) repeating steps (i) and (ii) for a number of times and determining the sequence of the fragment by comparing the quantities recorded for each sticky end sequence.
- The method can be used for the simultaneous sequencing of a heterogeneous population of nucleic acid fragments without spatially resolving them (see abstract and claims).
- D3 from the Darwin Molecular Corp., describes a method for determining the sequence of a nucleic acid molecule which comprises: (a) generating tagged nucleic acid fragments which are complementary to a selected target nucleic acid, where a

tag is correlative with a particular nucleotide and detectable by non-fluorescent spectrometry or potentiometry; (b) separating the tagged fragments by sequential length; (c) cleaving the tags from the tagged fragments; and (d) detecting the tags by non-fluorescent spectrometry or potentiometry, and from this determining the sequence.

Also disclosed in this document are compounds of the formula Tms-L-X and where: Tms = an organic group detectable by mass spectrometry comprises carbon, at least one of H and F, and optional atoms selected from O, N, S, P and I; L = an organic group which allows a Tms-containing moiety to be cleaved from the remainder of the compound, where the Tms-containing moiety comprises a functional group which supports a single ionised charge state when the compound is subjected to mass spectrometry and is selected from tertiary amine, quaternary amine and organic acid; and X = a functional group selected from hydroxyl, amino, thio, carboxylic acid, haloalkyl and derivatives of these which activate or inhibit the activity of the group toward coupling with other moieties, or is a nucleic acid fragment attached to L at other than the 3' end of the fragment; provided that the compound is not bonded to a solid support through X nor has a mass of less than 250 Daltons (see abstract and claims).

The methods and compounds described may be used e.g. for determining the sequences of nucleic acid molecules. They may be used for determination of multiple nucleic acid sequences simultaneously. The methods and compounds of WO-A-97 27331 allow sequencing to be performed with enhanced speed and sensitivity.

These documents, therefore, would appear to disclose the subject-matter of claims 1, 21, 22, 23 and 24 of the present application.

However, it is assumed that the priority date of the present application is validly claimed. The present priority date of 11/7/97 is, namely, before the publication dates of 16/4/98(WO-A-98 15652) and 31/7/97(WO-A-97 27331). Documents D2 and D3 could become relevant for the assessment of novelty in a future regional phase before the EPO.

Section VII

1. In order for the application to be self-contained (see further the PCT Guidelines, C-II, 4.17), the references to patent applications numbers should have been changed to publication numbers throughout the description.

Section VIII

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/02048

1. Claims 1, 21, 22, 23, 24 and 25, 26 do not meet the requirements of Article 6 PCT. Because claims 21, 22, 23 and 24 comprise all the features of claim 1, these claims should have been formulated as claims dependent on the latter (Rule 6.4 PCT).
2. The applicant attention is called to the fact that there appear to be more international applications from the same applicant (for example PCT/US 98/02044) designating the same states and the claims of those applications have the same priority date and relate to the same invention, thus the applicant may be required in the national phase to choose which one of those applications he wishes to proceed to grant (see further the PCT guidelines, C-IV, 6.3).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :
C12Q 1/68

A1

(11) International Publication Number: WO 99/02728

(43) International Publication Date: 21 January 1999 (21.01.99)

(21) International Application Number: PCT/GB98/02048

(22) International Filing Date: 13 July 1998 (13.07.98)

(30) Priority Data:

9714717.7 ✓	11 July 1997 (11.07.97)	GB
9714715.1 ✓	11 July 1997 (11.07.97)	GB
9719284.3 ✓	10 September 1997 (10.09.97)	GB

(71) Applicant (for all designated States except US): BRAX GENOMICS LIMITED [GB/GB]; 13 Station Road, Cambridge CB1 2JB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHMIDT, Günter [DE/GB]; Houghton Manor, Houghton, Cambs PE17 2BQ (GB). THOMPSON, Andrew, Hugin [GB/GB]; 25 Knoll Park, Alloway, Ayr KA7 4RH (GB).





(74) Agents: DANIELS, Jeffrey, Nicholas et al.; Page White & Farrer, 54 Doughty Street, London WC1N 2LS (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, (US), UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: CHARACTERISING NUCLEIC ACIDS



(57) Abstract

A method for characterising DNA, which comprises: (i) providing a population of DNA fragments, each fragment having cleavably attached thereto a mass label for identifying a feature of that fragment; (ii) separating the fragments on the basis of their length; (iii) cleaving each fragment in a mass spectrometer to release its mass label; and (iv) determining each mass label by mass spectroscopy to relate the feature of each fragment to the length of the fragment.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

Characterising Nucleic Acids

The present invention relates to a method for characterising DNA, especially to obtain sequence information.

Conventional DNA sequencing uses a DNA polymerase to add numerous dideoxy/deoxynucleotides to an oligonucleotide primer, annealed to a single stranded DNA template, in a template specific manner. Random termination of this process is achieved when terminating nucleotides, i.e. the dideoxynucleotides, are incorporated in the template complement. In this way, a series of fragments is produced containing all possible lengths of the template complement. A 'DNA ladder' is produced when the randomly terminated strands are separated on a denaturing polyacrylamide gel. Sequence information is gathered, following polyacrylamide gel electrophoresis, by detecting the 'DNA ladder' either through incorporating a radioactive isotope or fluorescent label into one of the nucleotides or the primer used in the reaction. A particular drawback with this technology is its dependence on conventional gel electrophoresis, to separate the DNA fragments in order to deduce sequence information, as this is a slow process taking up to nine hours to complete.

WO97/27331 describes methods for determining nucleic acid sequences in which mass spectrometry is used to detect tags from tagged nucleic acid fragments complementary to a selected target nucleic acid molecule. WO97/27331 proposes cleaving tagged fragments by photolysis followed by subsequent mass spectroscopic determination of purified tags. This method suffers from a number of drawbacks, including the need for expensive equipment to perform the photolysis step.

The present invention aims to overcome the drawbacks of the prior art.

Summary of the Invention

The present invention provides a method for characterising DNA,

- 2 -

which comprises:

- (i) providing a population of DNA fragments, each fragment having cleavably attached thereto a mass label for identifying a feature of that fragment;
- (ii) separating the fragments on the basis of their length;
- (iii) cleaving each fragment in a mass spectrometer to release its mass label; and
- (iv) determining each mass label by mass spectroscopy to relate the feature of each fragment to the length of the fragment.

By cleaving each fragment within the spectrometer the present invention possesses advantages over the use of cleavage outside the mass spectrometer, for example by chemical or photolytic cleavage. By designing mass labels which cleave within the mass spectrometer the need for expensive laser equipment or an additional cleavage chamber or interface between separating the fragments and determining the mass label to mass spectrometry is avoided. Cleavage in the mass spectrometer may take place using the ionisation process to induce fragmentation of each mass label. This is described in further detail below. For example, each mass label may be cleavably attached to its respective fragment by a linker which is cleavable in the mass spectrometer.

The method of characterising DNA according to the present invention finds particular application in DNA sequencing. In one aspect, the method further comprises:

- (a) providing at least one DNA single-stranded template primed with a primer; and
- (b) generating the population of DNA fragments from the at least one template, wherein the population comprises at least one series of DNA fragments, the or each series containing all possible lengths of a second strand of DNA complementary to the or each template;

wherein the feature of each fragment determined by each mass label relates to a nucleotide or nucleotide sequence at one end of each fragment, so that each nucleotide is related to a

position in the template associated with the mass label so as to deduce the sequence of the or each template.

In a preferred arrangement, the step of separating the fragments is effected by capillary electrophoresis. Capillary electrophoresis systems are amenable to microfabrication which avoid many of the problems associated with conventional gel electrophoresis, most notable of which is the time required for separation of bands. In a micro-fabricated capillary, this can be of the order of minutes rather than hours. Further, because the separation medium can be liquid, loading of capillaries can be easily automated.

The present invention can therefore avoid the limiting step in conventional sequencing techniques of resolution of the fragment population generated by the polymerisation in the presence of blocking nucleotides. The polymerase reaction is simple and relatively fast and can be readily performed in parallel. This is advantageous as it increases throughput. The rapidity, in comparison with the iterative approaches described in GB9620769.1 and GB9700760.1, reduces the time available for secondary structure formation in the templates which can impede chemical and biological steps in the sequencing process.

Thus, by removing the slab gel electrophoretic steps of the prior art, the overall speed of cDNA sequencing can be increased significantly by using capillary electrophoresis and mass spectrometry to derive sequence information.

In one arrangement, the series of DNA fragments is provided by contacting the template in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the

- 4 -

second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, and wherein each fragment is terminated with one of the probes.

In a further arrangement, at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each template in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, wherein each fragment is terminated with one of the probes, and wherein each set of mass labels from each set of four probes associated with each reaction zone is different from the other sets of mass labels; and the fragments are pooled before step (ii).

The present invention is a development of earlier patent applications on primer extension sequencing (GB 9620769.1 and GB 9700760.1). The earlier inventions describe methods for sequencing where a template sequence is determined in an iterative process. The processes described in these earlier patents are potentially limited in the read-length achievable by the efficiency of the chemical and biological reactions occurring in each iteration of the process.

The sequencing process of the present invention allows one to sequence large numbers of Sanger ladder populations, generated in parallel, simultaneously in a fully automated process. This

invention thus includes a method for automating the preparation of a large number of Sanger sequencing reactions allowing a large number of templates to be sequenced in parallel.

In a preferred arrangement, the primed DNA may be immobilised on a solid phase support such as a bead or the well of a microtitre plate.

The mixture of nucleotides used in the method typically comprises ATP, TTP, CTP and GTP although their analogues may also be used. All four nucleotides are usually required to ensure that they are sufficient for forming a second strand of DNA to hybridise to the template.

Preferably, the modified nucleotides are dideoxy- or deoxynucleotides which may be added in a concentration suitable to ensure random incorporation into the polymerase reaction. In this way, the DNA ladder of fragments may be produced.

The mass labels may be uniquely resolvable in mass spectrometry in the sense that their mass/charge ratio and/or fragmentation patterns characterise each mass label uniquely so that it may be assigned to a corresponding probe and thereby a corresponding modified nucleotide so that the nucleotide present in the target template sequence may be deduced because it hybridises with the modified nucleotide of the probe. For a simple non-multiplexed method for sequencing DNA it is sufficient to have only four probes, each with its respective modified nucleotide. In other words, four separate mass labels would be required in this simple method. In a multiplexing method, however, multiples of four probes are typically required, the mass labels of each group of four being different from one another. Each group of four mass labels must also be different from the other groups of mass labels so that it is clear which mass label is associated with which reaction zone.

The reaction zones of the present invention are typically

separate containers and may conveniently be microtitre wells in a microtitre plate.

In one arrangement according to the present invention a single primed DNA single-stranded template is present in each reaction zone. However, it is possible to have up to four different templates in each separate reaction zone although one or two templates are preferred. Where more than one template is used in each reaction zone the same four probes are used. Statistically it is possible still to assign a unique sequence to each template. Preferably, the relative concentrations of each template are known in this method. This is discussed in further detail below.

In a further arrangement, the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each template in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a probe containing only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein either the primer or the modified nucleotide of the probe is cleavably attached to the mass label, which mass label is associated with the reaction zone and uniquely resolvable in mass spectrometry from the mass label in the other reaction zones for identifying the modified nucleotide used in the reaction zone; and the fragments are pooled before step (ii).

In accordance with this method each separate reaction zone contains only one of the four possible modified nucleotides attached to a probe to terminate the polymerisation process. Thus, in each individual reaction zone a DNA ladder corresponding

- 7 -

to a template sequence terminating in either As, Ts, Gs or Cs would be formed. By repeating the method for each of the four nucleotides in separate reaction zones the full sequence of the template may be deduced. In this method either the probe or the primer may have cleavably attached thereto its corresponding mass label.

In a further arrangement, the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting the plurality of templates in each of four separate reaction zones in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a probe containing in each of the reaction zones only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein the primer is cleavably attached to the mass label, which mass label is associated with the primer and uniquely resolvable in mass spectrometry from the mass labels associated with the other primers used in the reaction zone; and wherein each nucleotide from its corresponding reaction zone is related to its position in the template.

In a further arrangement, the at least one template is four sets of DNA single-stranded templates, each set comprising an identical plurality of DNA single-stranded templates and the series of DNA fragments is provided by contacting each set in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary thereto, wherein the mixture further comprises a probe containing in each of the reaction zones only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising

- 8 -

to the second strand of DNA but blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein each of the templates of the four sets is primed with a primer to which the mass label is cleavably attached, which mass label which uniquely resolvable in mass spectrometry from the mass labels corresponding to the other templates and which is relatable to its respective template and its respective reaction zone, wherein the fragments are pooled before step (ii), and each nucleotide from its corresponding reaction zone is related to its position in the template.

The plurality of single-stranded templates may be primed by hybridising to a known sub-sequence common to each of the templates an array of primers each comprising a base sequence containing a common sequence complementary to the known sub-sequence and a variable sequence of common length, usually in the range 2 to 6, preferably in the range 2 to 4, more preferably 3. The array contains all possible sequences of that common length and the mass label cleavably attached to each primer is relatable to the variable sequence. The variable sequence is relatable to the particular template to be sequenced.

In a further arrangement, the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each set of templates in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary thereto, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, wherein each fragment is terminated with one of the probes, and wherein each set of mass labels from each set

of four probes associated with each reaction zone is different from the other sets of mass labels and, before step (ii), the fragments are pooled and the pooled fragments are sorted according to a sub-sequence having a common length of 3 to 5 bases adjacent to the primer to form an array of groups of sorted fragments, wherein each group is spatially separated from the other groups.

In a preferred arrangement, the step of sorting the pooled fragments comprises contacting the fragments with an array of spatially separate oligonucleotides each comprising a base sequence containing a common sequence complementary to the primer sequence of the fragments and a variable sequence of the common length, which array contains all possible variable sequences of the common length. The common length is preferably 4, in which case an array of 256 spatially separate oligonucleotides is required. The array of spatially separate oligonucleotides is conveniently a hybridisation array and may comprise a hybridisation chip.

In an alternative arrangement, the series of DNA fragments is provided by

(i) contacting the template in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the templates in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible lengths of the second strand of DNA, each second strand terminated with one of the probes;

(ii) removing unpolymerised nucleotides;

(iii) unblocking the modified nucleotides; and

(iv) contacting the series of templates with an array of

- 10 -

oligonucleotide probes, wherein each oligonucleotide probe has a nucleotide sequence of common length 2 to 6, all combinations of sequences are present in the array, and wherein each probe is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the nucleotide sequence.

In accordance with this arrangement, the series of templates forms a DNA ladder to which the oligonucleotide probes may be ligated. This method may be extended in a further arrangement in which the at least one template is a plurality of primed DNA single-stranded templates, each at a unique concentration, and the series of DNA fragments is provided by

(i) contacting the templates in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the templates, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the templates in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible lengths of the second strand of DNA, each second strand terminated with one of the probes;

(ii) removing unpolymerised nucleotides;

(iii) unblocking the modified nucleotides; and

(iv) contacting the series of templates with an array of oligonucleotide probes, wherein each oligonucleotide probe has a nucleotide sequence of common length 2 to 6, all combinations of sequences are present in the array, and wherein each probe is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the nucleotide sequence.

The nucleotide probes used to extend the DNA ladder hybridised to the series of templates preferably has a sequence of common

- 11 -

length 3 to 5, most preferably 4 nucleotides. In this way, 256 sequences would be present in the array.

The mass label to which each probe is cleavably attached in these alternative methods need not be cleaved in a mass spectrometer and can be cleaved outside the mass spectrometer, for example by photocleavage or chemical cleavage.

In a further alternative method, the series of DNA fragments is provided by contacting the template in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, and the series of fragments contains all possible lengths of the second strand of DNA of integer multiples of 1, in which each fragment is terminated with one of the probes.

The at least one template may be a plurality of primed DNA single-stranded templates each at a unique concentration. In this particular embodiment, the series of DNA fragments is provided by contacting the templates in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary to the templates, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises

- 12 -

a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, and the series of fragments contains all possible lengths of the second strand of DNA of integer multiples of 1, in which each fragment is terminated with one of the probes.

L is preferably 3 to 5, most preferably 4, and once again, the mass labels to which the oligonucleotide probes are cleavably attached need not be cleaved within the mass spectrometer and could be cleaved outside, for example by photolysis or chemical cleavage.

In these further alternative arrangements, instead of producing a DNA ladder with a spacing of one base, a DNA ligase is used and a spacing of 2 to 6 bases is used. This is therefore a ligase chain reaction.

In a further aspect the present invention provides a set of nucleotide probes for use in a method of sequencing DNA from a primed DNA single-stranded template, which set of probes contains all four nucleotides for hybridising to the template, wherein the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to a second strand of DNA complementary to the template but blocked to prevent further polymerisation thereto, which modified nucleotide is cleavably attached to a mass label for identifying the modified nucleotide, and wherein each mass label when released from the probe is uniquely resolvable in relation to every other mass label in the set by mass spectrometry and is relatable to its corresponding modified nucleotide.

The set of probes may comprise a plurality of sub-sets of probes, each sub-set containing all four nucleotides for hybridising to the template.

- 13 -

In a further aspect the present invention provides a set of oligonucleotide primers, each of which comprises a mass label cleavably attached to an oligonucleotide primer base sequence for hybridising to a DNA single-stranded template to form a primed template, wherein each mass label of the set, when released from the primer, is uniquely resolvable in relation to every other mass label in the set by mass spectrometry and is relatable to the oligonucleotide primer base sequence.

The mass label of each probe or primer may be attached to the modified nucleotide or primer by a cleavable linker which may be cleaved under any appropriate cleavage conditions such as photocleavage conditions or chemical cleavage conditions. The mass labelled probes or primers may be made in accordance with any standard methodology including the methodology disclosed in PCT/GB98/00127 of 15th January 1998 filed by the present applicants.

The present invention will be described in further detail by way of example only with reference to the accompanying drawings, in which:

FIGURE 1 shows how PCR primers for each cloned fragment may be used in amplification;

FIGURE 2 shows the use of biotinylated PCR primers in fragment amplification;

FIGURE 3 shows the production of an immobilised single stranded template from double stranded PCR product;

FIGURES 4a and 4b show diagrammatically the method of a preferred embodiment of the present invention;

FIGURES 5 to 10 show diagrammatically the methods of further preferred embodiments of the present invention;

FIGURE 11 shows a schematic diagram of an orthogonal time of flight mass spectrometer suitable for use in the present invention;

FIGURE 12 to 14 show diagrammatically a method of an alternative embodiment of the present invention using reversably blocked

nucleotide probes; and

FIGURE 15 shows the results of the method of Figures 12 to 14.

Examples

Automated preparation of heterogenous template populations:

In order to produce a high throughput DNA sequencing technology the automation of the production of the sequencing template is highly desirable. The following is an outline which describes an automated method of producing sequencing templates for using in the present invention.

For a large scale sequencing project, for example a whole bacterial genome or a full YAC clone, the DNA must first be subcloned into a library. The process of producing a library of this sort can be done in-house or by commercially available services, such as that provided by Clonetech. The DNA is fragmented (e.g. by restriction enzyme digestion or sonification) to sizes in range of a few hundred bases and then subcloned into a cloning vector of choice. Because each fragment in the library is flanked by the same vector sequence a standard set of flanking PCR primers can be used to PCR amplify each each fragment. Using the same PCR primers for each fragment also helps normalise the efficiency of each PCR reaction as primer sequence is one of the most important factors affecting amplification efficiency. (see Figure 1)

The library is then transfected into an appropriate bacterial strain and the bacteria plated out onto selective agar plates. Individual colonies (each containing an unique fragment contained within the cloning vector) are then picked by a colony picking robot (which are commercially available). Each picked colony is then spiked into a unique PCR reaction, set up on a microtitre plate for example, and each fragment is PCR amplified using the standard primer set which flank the insert. One of the primers used in this reaction must be biotinylated which will allow the subsequent capture of the amplified fragment. (see Figure 2)

- 15 -

Following the PCR amplification, a known amount of each of the amplified fragments is then captured on a streptavidin coated surface by its biotinylated primer. By controlling the amount of available streptavidin a specific amount of PCR product can be captured. (This does, however, rely on all the primers being incorporated into the amplification products. This should only require a simple primer titration optimisation experiment as PCR reactions using clones are usually highly efficient.)

Different protocols can be used for this purpose, for example streptavidin coated magnetic beads or streptavidin coated wells of a microtitre plate. When using beads, which will bind 1 pmol of biotin per μ l of beads, adding 5 μ l of beads and the appropriate buffer to the PCR reaction will capture 5 pmol of the amplified fragment. The use of beads also allows the capture of different quantities of individual amplified fragments. By adding differing amounts of beads to separate amplification reactions prior to pooling them, one can, for example, create a heterogenous population with 1 pmol of fragment 1, 4 pmol of fragment 2, 10 pmol of fragment 3 and so on. Alternatively streptavidin coated wells of a microtitre plate could also be used by transferring each amplification reaction to a unique well of the microtitre plate. Commercially available streptavidin coated plates usually have a maximum binding capacity of between 5 to 20 pmol of biotin. Therefore, of the amount of amplified fragment captured to each well is determined by the binding capacity of that plate.

Following capture, excess amplified fragments are then washed away, the double stranded PCR product is denatured with either alkali or heat (or both) (to free the non-biotinylated strand). The non-biotinylated strand is then washed away and this leaves a single stranded template immobilised in the well or tube ready to be used in a sequencing reaction. (see Figure 3)

DNA Sequencing Using Mass Labelled dNTP's

Figures 4a and 4b illustrate diagrammatically the method of DNA

sequencing using mass labelled dNTP's described below.

An immobilised single stranded DNA template is prepared from a PCR product (see above) or by any other appropriate means. Immobilisation can be achieved by biotinylating one of the primers used in the PCR reaction which then allows the subsequent capture of the PCR product to either streptavidin coated beads or wells of a microtitre plate. Following capture, the non-immobilised strand is denatured by alkali or heat (or both) and washed away. The other (non-biotinylated) PCR primer is then annealed to its complementary site on the single stranded PCR product to act as a sequencing primer for a DNA polymerase.

Extension of the sequencing primer is achieved by incubating the template with nucleotide triphosphates, mass labelled deoxynucleotides present at a low concentration and a DNA polymerase (e.g. taq, *E. Coli*, T7 DNA polymerases or their derivatives - acting in a template specific manner), with appropriate conditions and time. Extension of the primer is blocked in individual templates with a known probability due to the presence of blocking groups on the mass labelled deoxynucleotides (this can be the unique 'mass label' itself) which prevents the 3'OH of the deoxynucleotides reacting with the 5' triphosphates of further nucleotide, thus preventing the addition of any more bases by the polymerase. This is shown in step 1 of Figure 4a where the Sanger reaction is performed on each template separately using terminating nucleotides that carry mass labels. The unique mass labels are attached to the deoxynucleotides by a cleavable linker group. Cleavage is carried out here by laser light (or possibly by chemical or other means). On cleavage, the mass label is released into solution for analysis.

This embodiment is akin to traditional Sanger sequencing where the blocked nucleotides are present at a low concentration in the presence of ordinary triphosphates. This allows one to generate a Sanger ladder of fragments. In this embodiment the efficiency

- 17 -

of photocleavage of the mass labels is not critical to the readlength achievable. One requires just a single sequencing reaction, which means that template is not left standing for long periods of time. Similarly, the potential for photodamage due to repeated photolytic reactions required in the iterative approach of patents GB 9620769.1 and GB9700760.1, is avoided. One can analyse the resultant sequence ladder by capillary electrophoresis followed by direct analysis of mass labels by electrospray mass spectrometry (ESMS).

In step 2 of Figure 4a, multiple templates are fed into the same capillary electrophoresis electrospray mass spectrometry system. As each band passes through, the mass labels are cleaved by photolysis and injected into an electrospray mass spectrometer for analysis. In a preferred arrangement, no photocleavage apparatus is present and, instead, the mass labels are designed so that, upon entry into the mass spectrometer, the conditions of ionisation are such that the mass labelled fragments cleave and the mass labels are then analysed. As shown in Figure 4b, the identity of mass labels determines the identity of the nucleotide and the source template from which the sequence is derived.

The use of labelled nucleotides is the preferred format as this avoids certain problems associated with primer labelled sequencing, which is also possible with mass labelling. Polymerase reactions do often terminate prematurely, without the intervention of blocked nucleotides. This is a problem with primer labelled sequencing because the premature termination generates a background of labelled fragments that are terminated incorrectly. Labelling the blocking nucleotides ensures only correctly terminated fragments are labelled so only these are detected by the mass spectrometer. This then permits cycle sequencing where multiple rounds of primer are added to the template. The sequencing reaction is performed using a thermostable polymerase. After each reaction the mixture is heat denatured and more primer is allowed to anneal with the template.

- 18 -

The polymerase reaction is repeated when primer template complexes reform. Multiple repetition of this process gives a linear amplification of the signal, enhancing the reliability and quality of the sequence generated.

This invention further avoids problems associated with fluorescence based methods. The large differences in sizes of the commercially available fluorescent labels causes differences in migration of templates of similar length. Since any set of 4 labels used to identify a sequencing reaction can be chosen to be very close in size since a mass spectrometer will comfortably detect differences in mass of one dalton, which should have minimal effect on the relative migration of any given template.

Multiplexing Sanger Ladders:

Given a large number of mass labels one can multiplex a series of Sanger sequencing reactions by labelling the 4 blocking nucleotides with a different set of 4 mass labels in each reaction. Each sequencing reaction would be performed separately and then all the templates would be recombined at the end of the sequencing reactions. The Sanger ladders generated are then all separated together by a single capillary electrophoresis step feeding fragment bands directly into a mass spectrometer for analysis of the labels. Each set of 4 mass labels then correlates to a single source template.

Simultaneous sequencing:

This invention avoids the need for stringent quantitation. One can however exploit limited quantitation with this invention to compress the number of mass labels needed to sequence a number of templates in parallel. Consider the case where one has 16 labels evenly spread across a clearly distinguishable mass range. One could assign the first four labels to the bases A, C, G, T in that order and use deoxynucleotides labelled in this way to sequence the first template. In a similar manner three other templates can be sequenced. Given that there is a roughly 1 in 16 chance that the same base will appear at the same point in two

- 19 -

reactions one can use the same label in two separate reactions, labelling different bases if desired. If two reactions share all 4 labels one can double the number of parallel reactions that can be analysed. If by chance two templates have the same base at a point, clearly only one label will appear for two templates so they clearly share a base. Limited quantitation would be needed to reassign the base calls for each band leaving the capillary electrophoresis system to its source template, but as long as the quantities of templates sharing a set of labels are distinct, this should be relatively simple to do. Furthermore the templates could be sequenced in a single reaction. More templates could be sequenced simultaneously with more stringent quantification of each template. One would need to know in advance how many templates one was sequencing in each reaction and how much of each was present at the start. This may preclude one from using cycle sequencing in which there is a linear amplification of template, if distortion of quantitation cannot be calibrated for.

Separation Techniques:

The separation of a Sanger Ladder by gel electrophoresis imposes limitations on the throughput and accuracy achievable for DNA sequencing. The polymerase reaction used to generate a Sanger ladder is simple and relatively fast and can readily be performed in parallel or even multiplexed in the same reaction. Various novel sequencing methods have been developed that are compatible with PCR and hence exploit automation using 96 well plate robotics and thermocyclers.

Gel electrophoresis works on the simple principle that a charged molecule placed between two electrodes will migrate towards the electrode with the opposite charge to its own. The larger the molecule is for a given charge the more slowly it will migrate towards the relevant electrode. Nucleic acids are poly-ions, carrying approximately one charge per nucleotide in the molecule. This means that nucleic acids of any size migrate at approximately the same rate ignoring frictional forces from the

- 20 -

separation medium. The effect of frictional forces is related to the size of the molecule or in the case of nucleic acids, the length of the molecule. This means that nucleic acids are effectively separated by length. The role of the gel matrix is to provide frictional force to impede migration. The speed of separation is proportional to the size of the electric field between the two electrodes. This means that increasing the size of the electric field will reduce separation times, however the electrical resistance of the separation medium means that heat is generated as a result of the electric field and the heat increases with the electric field. The higher temperatures increase the kinetic energy imparted to the analyte leading to greater diffusion and band broadening. This reduces the resolution of the separation. Gels can be cooled but heat dissipation from a slab gel is limited by its surface/volume ratio which is essentially a function of the thickness of the gel. Thinner gels dissipate heat better but there is an additional effect of increased resistance. This means that in slab gel techniques using gels of 200 to 400 μm thickness heating becomes severe if the electric field strength is greater than 50 V/cm. Replacement of the slab gel electrophoretic steps is the most attractive target in view to increasing the overall speed of DNA sequencing.

Capillary electrophoresis offers significant advantages over gel electrophoresis as a separation technology. Various approaches to capillary electrophoresis exist but for nucleic acid separations capillary gel electrophoresis is often used. This technique is essentially gel electrophoresis in a narrow tube. The use of a capillary gives an improved surface/volume ratio which results in much better thermal dissipation properties. This allows much higher electric fields to be used to separate nucleic acids greatly increasing the speed of separations. Typically capillaries are 50 to 75 μm wide, 24 to 100 cm long and electric fields up to 400 v/cm can be used although lower fields are used routinely. Increased separation speeds also improve the resolution of the separation as there is less time for diffusion

- 21 -

effects to take place and so there is less band broadening. Improved resolution permits greater read lengths, increasing throughput further. The introduction of flowable polymers has meant that time consuming and technically demanding steps of gel preparation associated with slab gel electrophoresis can be avoided and capillaries can be prepared by injection of the sieving matrix. This improves the reproducibility of separations and the injection of polymers is a process which is readily automated.

Multiplexing Sequencing Reactions:

Primer labelled sequencing is also possible with mass labelling which has certain advantages over nucleotide labelled sequencing. Consider the situation where one has a number of templates each with distinct primer sequences. One can label each unique primer with a unique mass label. The template mixture can be divided into four reactions in which only one of each of the four terminating dideoxynucleotides is present. Each template is primed with its uniquely labelled primer. After performing each of the four Sanger reactions, one can resolve each ladder by capillary electrophoresis mass spectrometry. Each band that elutes from the capillary electrophoresis column that contains a terminated fragment can be related back to its source template by the label linked to its primer. In this way a large number of templates can be sequenced simultaneously in the same reaction.

For each template with a unique primer sequence, one could choose to label the unique primer with a different label in each of the four reactions to identify which terminating nucleotide is present. This would allow one to pool the four individual base sequencing reactions and analyse them simultaneously. This has the advantage that all four reactions are analysed under identical conditions which should avoid ambiguities that might arise when analysing the four reactions separately due to variations in conditions in each analysis.

The advantage of labelling nucleotides in order to detect only

- 22 -

correctly terminated nucleotides is lost by labelling the primer. This advantage could be conferred to primer labelling by modifying the terminating nucleotides to carry a marker to allow correctly terminated fragments to be retained for example by affinity to a column. A plausible modification would be addition of (biotinamido)pentylamine to the terminating nucleotides which would allow reversible binding to avidin. For normal sanger sequencing where only one template is analysed at a time this is probably not worthwhile whereas for reactions where many templates are sequenced simultaneously the additional cost of the separation would be tolerable for the improved quality of the sequence data that would be generated.

Preparation of templates with unique primers:

In order to permit simultaneous sequencing reactions with mass labels one requires that each template be identifiable with a uniquely labelled sequencing primer. One could conceivably engineer a family of cloning vectors that bear different primer sequences flanking the integration site for the exogenous DNA to be sequenced. Each sequencing reaction would be performed on a group of templates where only one template derived from each vector type is present so that all the templates in a reaction bear unique primers. Further details of these methods are described in copending International Patent Application filed on 13th July 1998 by the present applicants [PWF Ref: 87847]

Adaptors to introduce primers to restriction fragments:

One can, however, exploit the ability to sequence numerous templates simultaneously to cut out sub-cloning steps in a sequencing project. Consider a large DNA fragment such as a mitochondrial genome or a cosmid. One can cleave such a large molecule with a frequently cutting restriction enzyme to generate fragments of the order of a few hundred bases in length. If one uses a restriction endonuclease like *Sau3A1* one is left with fragments with a known sticky end to which one can ligate adaptors bearing a known primer sequence.

- 23 -

This approach is shown diagrammatically in Figure 5. In step 1, a genomic DNA clone is treated with a frequent cutting restriction endonuclease such as Sau3A1. In step 2, adapters are ligated to the restriction fragments bearing specific primer sequences. All fragments are dealt with simultaneously although, for simplicity, only one is shown in the Figure. In step 3, the DNA is denatured after an optional amplification step and optional cleaning up steps to remove unligated adapters and restriction enzymes. Figure 6 shows a continuation of this process in which the single-stranded DNA is captured using an immobilised primer complementary to the adapter primer sequence. In step 5, the immobilised primer and appropriate polymerase is used to generate a complementary strand. In step 6, the free strand is melted off and washed away or recaptured onto immobilised primer to generate further copies of template, if desired. In Figure 7, mass labelled primers are added at step 7. The mass label identifies bases overlapping into unknown sequence. By step 8, the majority of DNA molecules in a small population should be uniquely primed in this way and a primed population can thus be used for extension in a Sanger sequencing or cycle sequencing reaction.

Similar steps are shown in Figures 8 to 10.

The majority of properly restricted fragments should as a result bear an adaptor at each of their termini. This permits amplification of the adapted restriction fragments at this stage if that is desired. After adapting and any amplification, one denatures the adapted fragments and hybridises these fragments to a 'capture' primer. The capture primer could be biotinylated and presented to the adapted fragments free in solution, after which captured fragments can be immobilised onto a solid phase support derivitised with avidin. Alternatively the primer could be immobilised onto a solid phase support prior to exposure to the adapted restriction fragments. At this stage one would divide one's template into four separate pools in order to sequence each pool with a different terminating nucleotide.

- 24 -

The captured fragments are made double stranded at this stage by reaction with a polymerase. This means that immobilised copies of all sequences should be present. The hybridised strand can be melted off at this stage and be disposed of if that is desired. An immobilised complementary strand is retained. One can also amplify the sequence present at this stage by further hybridisation with capture primer.

After denaturing free DNA from the immobilised copies of the template and disposing of free DNA, one can add a series of 'sequencing' primers to the reaction. These primers bear the primer sequence in the adaptor and the restriction site by which the adaptors were originally ligated to the DNA and an additional overlap of a predetermined number of bases. If one has 64 labels available the overlap can be 3 bases. Each of the possible 3 base overlaps can be identified by a unique mass label. Given a population of the order of 50 to 60 templates one would expect the majority to have a different 3-mer adjacent to the ligated primer. Thus the majority of templates will be expected to hybridise to a distinct primer. Any template that bears a 3-mer immediately adjacent to the adaptor that is the same as that on another template would only be resolvable if one is able to determine by the quantity of each template which template to assign a base call to.

With the majority of templates primed with a unique primer one can add polymerase, nucleotide triphosphates and one of the four blocking nucleotides to each reaction and can generate Sanger ladders (Figure 10, step 8). If a thermostable polymerase is used, then the ladders can be denatured at the end of each cycle and fresh primers can be added. If cycle sequencing is used then one would almost certainly want some means to select for properly terminated fragments since cycle sequencing not only amplifies the number of properly terminated fragments but also the number of improperly terminated fragments.

The sanger ladders from each of the four sequencing reactions are

- 25 -

then preferably pooled (Figure 10, step 9) and analysed together by capillary electrophoresis mass spectrometry so as to avoid any ambiguities in assigning bases due to experimental differences. Each pool of templates would thus have to have its primers labelled with a unique set of mass labels. Thus a total of 256 mass labels would be required. Each primer thus has four labels, one for each terminator reaction. The labels assigned to each primer should be close in mass and size to minimise differences in migration between each termination reaction.

Multiplexing with nucleotide labelled reactions:

A further embodiment of this invention is multiplexing multiple templates in reactions with labelled nucleotides.

Consider a reaction in which unmodified ATP, CTP, GTP and TTP are present with the four corresponding uniquely mass labelled terminating nucleotides. One can generate Sanger ladders for a number of templates simultaneously in the same reaction vessel. If these different templates share a sequencing primer, they can be subsequently sorted into separate groups prior to separation on the basis of the sequence immediately adjacent to the primer. One could separate the fragments onto a hybridisation array where the array bears a sequence complementary to the sequencing primer at all points and an additional predetermined number of bases, N, such that each location on the array bears just one of the possible N base sequences. This means if N is 4 there would be 256 discrete locations on the array. It is expected that a group of templates would in most cases have distinct sequences immediately adjacent to the primer.

This would be an expensive exercise for sorting templates from just one reaction vessel. With a large number of mass labels, however, one can have distinct sets of 4 mass labels identifying blocking nucleotides in a large number of reactions. Thus multiple templates can be added to different reaction vessels, preferably different templates to each reaction vessel. After generating Sanger ladders in each vessel, the reactions can be

- 26 -

pooled and the templates from each reaction can be sorted simultaneously. One would expect the majority of ladders of each template from each reaction to segregate to discrete locations on an array and that each location on the array would receive template ladders from a number of distinct reactions.

Having sorted ladders to discrete locations on an array one needs to separate the ladders from each location and identify the mass labels that terminate each set of fragments of each length. How one does this would depend on the array used.

Practically speaking, a hybridisation array could comprise an array of wells on microtitre plates, for example, such that each well contains a single immobilised oligonucleotide that is a member of the array. In this situation a sample of the pooled reactions is added to each well and allowed to hybridise to the immobilised oligonucleotide present in the well. After a predetermined time the unhybridised DNA is washed away. The hybridised DNA can then be melted off the capture oligonucleotide and loaded into a capillary electrophoresis mass spectrometer.

Equally the array could be synthesised combinatorially on a glass "chip" according to the methodology of Southern or that of Affymetrix. One could hybridise the pooled sanger ladders to the chip and wash away unhybridised material. If the probes of the array are immobilised with a linker containing a photocleavable group, ladders from discrete locations on the array could be released into solution by application of laser light to the desired location on the array. The solution phase ladders can again be simply loaded into a capillary electrophoresis mass spectrometer.

Again, the advantage of multiplexing and sorting templates is the ability to avoid a number of subcloning steps in a large scale sequencing project. One would prepare template as described above for primer labelled multiplexing but at the stage when sequencing primer is added, the primers used would not be mass


- 27 -

labelled. The blocking nucleotides in each reaction would be labelled instead.

Features of Mass labels:

To achieve the required behaviour from a mass label, certain chemical properties are desirable. These are represented in particular molecular groups or moieties that can be incorporated into mass labels in a number of ways.

For the purposes of generating mass labels, favoured labels require a cleavable bond in the linker and fragmentation resistant bonds in the mass label.



For optimal performance using present techniques a mass/charge ratio of up to 2000 to 3000 units is the optimal range for such labels as this corresponds to the range over which singly charged entities can be reliably detected with greatest sensitivity, however labels of mass less than 100 to 200 daltons are not ideal as the low mass end of the spectrum tends to be populated by solvent molecules, small molecule impurities, multiple ionisation peaks and fragmentation peaks.

To permit detection one requires labels that have a net charge, but are preferably not multiply ionisable, i.e. they have a fixed single charge. Furthermore they should be resistant to fragmentation. This ensures that each peak in the mass/charge spectrum corresponds to a single label and simplifies the analysis of the data. Furthermore this reduces any ambiguity in the determination of the quantity of the label, which is very important for some of the applications for which this invention has been developed.

Various functionalities exist which carry or can carry positive charges for positive ion mass spectrometry. These include but are not limited to amines particularly tertiary amines and quaternary amines. Quaternary ammonium groups carry a single positive charge and do not require ionisation. For positive ion spectrometry these allow great sensitivity. Hence preferred positive ion mass labels should carry at least one such group.

Various functionalities are available to carry a negative charge for negative ion mass spectrometry which include but are not limited to carboxylic acids, phosphonates, phosphates, phenolic hydroxyls, sulphonic acids, sulphonilamides, sulphonyl urea, tetrazole and perfluoro alcohol.

Ionisation techniques:

For many biological mass spectrometry applications so called 'soft' ionisation techniques are used. These allow large molecules such as proteins and nucleic acids to be put into the mass spectrometer in solutions with mild pH and at low concentrations. Two such techniques are ideal for use with this invention; electrospray ionisation and Matrix Assisted Laser Desorption Ionisation (MALDI).

Electrospray Ionisation:

Electrospray ionisation requires that the dilute solution of biomolecule be 'atomised' into the spectrometer, i.e. in a fine spray. The solution is, for example, sprayed from the tip of a needle across an electrostatic field gradient or into a stream of dry nitrogen in an electrostatic field. The mechanism of ionisation is not fully understood but is thought to work broadly as follows. In a stream of nitrogen the solvent is evaporated. With a small droplet, this results in concentration of the biomolecule. Given that most biomolecules have a net charge this increases the electrostatic repulsion of the dissolved protein.

- 29 -

As evaporation continues this repulsion ultimately becomes greater than the surface tension of the droplet and the droplet 'explodes' into smaller droplets. The electrostatic field helps to further overcome the surface tension of the droplets. The evaporation continues from the smaller droplets which, in turn, explode iteratively until essentially the biomolecules are in the vapour phase, as is all the solvent. This technique is of particular importance in the use of mass labels in that the technique imparts a relatively small amount of energy to ions in the ionisation process and the energy distribution within a population tends to fall in a narrower range when compared with other techniques. The ions are accelerated out of the ionisation chamber through a pair of electrodes. The potential difference across these electrodes determines whether positive or negative ions pass into the mass analyser and also the energy with which these ions enter the mass spectrometer. This is of significance when considering fragmentation of ions in the mass spectrometer. The more energy imparted to a population of ions the more likely it is that fragmentation will occur. By adjusting the accelerating voltage used to accelerate ions from the ionisation chamber one can control the fragmentation of ions.

Matrix Assisted Laser Desorption Ionisation (MALDI):

MALDI requires that the biomolecule solution be embedded in a large molar excess of an photo-excitabile 'matrix'. The application of laser light of the appropriate frequency (266 nm beam for nicotinic acid) results in the excitation of the matrix which in turn leads to excitation and ionisation of the embedded biomolecule. This technique imparts a significant quantity of translational energy to ions, but tends not to induce excessive fragmentation despite this. Accelerating voltages can again be used to control fragmentation with this technique though.

MALDI techniques can be supported in two ways. One can embed mass labelled DNA in a MALDI matrix, where the labels themselves are not specifically excitable by laser or one can construct labels

- 30 -

that contain the necessary groups to allow laser energisation. The latter approach means the labels do not need to be embedded in a matrix before performing mass spectrometry. Such groups include nicotinic, sinapinic or cinnamic acid moieties. MALDI based cleavage of labels would probably be most effective with a photocleavable linker as this would avoid a cleavage step prior to performing MALDI mass spectrometry. The various excitable ionisation agents have different excitation frequencies so that a different frequency can be chosen to trigger ionisation from that used to cleave the photolysable linker. These excitable moieties are easily derivitised using standard synthetic techniques in organic chemistry so labels with multiple masses can be constructed in a combinatorial manner.

Fragmentation within the Mass Spectrometer:

Fragmentation is a highly significant feature of mass spectrometry. With respect to this invention it is important to consider how one intends to identify a mass label. At the two extremes one can either design molecules that are highly resistant to fragmentation and identify a label by the appearance of the label's molecular ion in the mass spectrum. One would thus design families of labels to have unique molecular ions. At the other extreme one can design a molecule with a highly characteristic fragmentation pattern that would identify it. In this case one must design families of labels with non-overlapping patterns or with at least one unique fragmentation species for each label by which to identify each label unambiguously. Fragmentation is, however, a property of the molecule and of the ionisation technique used to generate the ion. Different techniques impart differing amounts of energy to the ion and the chemical environment of the ions will vary considerably, thus labels that are appropriate for one mass spectrometry technique may be inappropriate in others. The preferred approach is to design fragmentation resistant molecules, although some fragmentation is inevitable. This means one aims to identify molecules with a single major species, either the molecular ion

or a single very highly populated fragment ion.

Determining bond stability in the mass spectrometer:

In neutral molecules it is reasonably simple to determine whether a molecule is resistant to fragmentation, by consideration of bond strengths. However, when the molecule is ionised, the bond strength may increase or decrease in ways that are difficult to determine a priori. For example, given a bond, X-Y, we can write:

In the equations above, $D(A-B)$ refers to bond energy of the species in parentheses, $I(N)$ refers to the ionisation energy of the species in parentheses and ΔH is the free energy of formation of the species in parentheses. The upshot of the equations above is that in order to predict whether a bond is likely to be stable under a given set of ionisation conditions we need to know the energy of ionisation of the molecule and the energy of ionisation of the neutral fragment that results from fragmentation at the bond in question.

For example, consider the C-N bond in aniline:

$$I(NH_2^+) = 11.14 \text{ electronvolts (ev)} \text{ and } I(C_6H_5NH_2) = 7.7 \text{ ev}$$

$$\therefore I(C_6H_5NH_2) < I(NH_2^+) \text{ by } 3.44 \text{ ev}$$

The alternative cleavage at this bond is:

$$I(C_6H_5^+) = 9.35 \text{ electronvolts (ev)} \text{ and } I(C_6H_5NH_2) = 7.7 \text{ ev}$$

$$\therefore I(C_6H_5NH_2) < I(C_6H_5^+)$$

This bond is thus not easily broken in the ion. Aniline, if it has sufficient initial energy to fragment, is generally observed to cleave releasing HCN, rather than by cleavage of a C-N bond.

- 32 -

$$I(OH^{\bullet}) = 13\text{ev and } I(C_6H_5OH) = 8.47\text{ev}$$

$$\therefore I(C_6H_5OH) < I(OH^{\bullet})$$

Similarly considerations apply to phenol:

The alternative cleavage at this bond is

$$I(C_6H_5^{\bullet}) = 9.35\text{ev and } I(C_6H_5OH) = 8.47\text{ev}$$

$$\therefore I(C_6H_5OH) < I(C_6H_5^{\bullet})$$

Thus C-O cleavage is not observed.

Determining the differences in ionisation energies of molecule and neutral fragments is a general working principle which can be used to predict likely ion bond strengths. If the energy added during ionisation is less than the ionic bond strength then ionisation will not be observed. Typical ionic bonds that have good strength include, aryl-O, aryl-N, aryl-S bonds. Generally, aliphatic type bonds become less stable in ionic form. Thus single C-C bonds are weak in the ion but C=C is still strong. Aryl-C=C tends to be strong too for the same reasons as aryl-O, etc. Aryl or Aryl-F bonds are also strong in ionic form which is appealing as fluorocarbons are cheap to manufacture and are chemically inert.

Similar considerations apply to negative ions, except one must use electron affinities in the equations above rather than ionisation energies.

Linkers to allow controlled release of mass labels:

Controllable release of mass-labels from their relevant molecule can be achieved in response to light or chemical triggers or can be achieved within the mass spectrometer through control of fragmentation. Photo-cleavable and chemically cleavable linkers can be easily developed for the applications described. Many are

commercially available.

Cleavage of mass labels within the mass spectrometer:


An alternative to chemical or photolytic cleavage is the use of the ionisation process to induce fragmentation of labels. One can design a linker that is highly labile in the ionisation process such that it will cleave when the molecule to which it is attached is ionised in a mass spectrometer. There are two factors to consider in controlling cleavage: 1) how much excess of energy is deposited on the ion during the ionisation process and 2) whether this excess is sufficient to overcome bond energy in the ion. The excess of energy deposited is strongly determined by the ionisation technique used. The bond energy is obviously determined by the chemical structure of the molecule being analysed.

Fragmentary linkers:

As discussed above certain groups are particularly resistant to fragmentation, while others such as aliphatic type bonds are reasonably susceptible to cleavage. In order to design a linker that cleaves in a specified location, one might design a molecule that is broadly resistant to fragmentation but that contains a 'weak link', whose fragment ion is stabilised by the surrounding molecule. Certain structural features are observed to stabilise fragments ions when cleavage occurs at certain bonds in a molecule. Linear alkanes are seen to fragment relatively randomly while molecules containing secondary and tertiary alkyl groups are seen to fragment most commonly at the branch points of the molecule due to the increased stability of the secondary and tertiary carbocations. Similarly double bonds stabilise adjacent carbocations through resonance or delocalisation effects. Similar effects are noted in bonds adjacent to aryl-C- groups.

For the purposes of generating a linker for mass labels, one requires a single mass spectrometrically weak bond in the linker

and strong ones in the mass label of the sorts described above. A typical weak bond would be:



Metastable ions and autocleavage of mass labels:

Stability in mass spectrometry is dependant on the ionisation technique used. Broadly speaking an unstable ion is a species that will fragment in the ionisation chamber. Similarly a stable ion will not fragment before reaching the detector. Metastable ions are thus ions that fragment somewhere between the ion source and detector. The temporal distinctions between the classes is somewhat dependant on the configuration of the mass spectrometer used. As mentioned before ionisation techniques have a considerable influence on the degree of fragmentation induced in a population of molecules so what may be a stable ion in electrospray ionisation may be highly unstable under electron ionisation. Furthermore the geometry of the separation stages of the mass spectrometer determines how long an ion exists before detection - ion trap mass spectrometers can obviously store ions for considerable periods of time before detection so molecules which in other geometries reach a detector in high abundance will have time in a trap to fragment.

These factors all have a bearing on the nature of molecule used as a mass label and as a linker. Clearly the design envelope available for such molecules is fairly large.

Induced cleavage of labels:

Various analytical techniques have been developed over the years to promote fragmentation of ions for use in structural studies and for unambiguous identification molecules on the basis of

- 35 -

fragmentation fingerprints. Most of the ionisation techniques will cause some degree of fragmentation but variations on chemical ionisation techniques can most simply be used to aid fragmentation. Electrospray ionisation can be modified slightly to promote fragmentation. The ionisation chamber can be modified to include a discharge electrode which can be used to ionise the bath gas which in turn will collide with the vaporised sample molecules increasing ionisation and fragmentation of the sample. This technique is termed Atmospheric Pressure Chemical Ionisation (APCI).

A more active approach to fragmentation entails inducing decomposition of molecules such as collision induced decomposition (CID). CID uses tandem mass analyser/spectrometer constructions to separate a stream of ions, then induce collision of the separated ion stream to promote fragmentation followed by analysis of the resultant ions by a second mass spectrometer. A typical tandem mass geometry comprises two quadrupole mass analysers separated by a collision chamber. This is just a chamber between the two quadrupoles into which a gas can be introduced to allow collision with the ion stream from the first mass analyser. The gas density in the collision chamber must not be too high to permit the collision fragments to pass through, for subsequent separation and analysis by the second quadrupole. Mass labelled molecules could be separated in tandem mass spectrometer so that the first quadrupole separates molecules into streams of a given mass/charge ratio followed by collision which would favour cleavage of labels which can then be analysed in a second mass analyser.

Other techniques are compatible with mass label technologies. A preferred method as discussed earlier is photon induced decomposition. Photon induced decomposition would involve the use of photocleavable mass labels. A typical geometry uses a tandem mass analyser configuration similar to those used in CID, but the collision cell is replaced with a photo-excitation chamber in

- 36 -

which the ion stream leaving the first quadrupole is subjected to laser light. High intensity lasers are required to ensure that a significant proportion of a fast moving ion stream interacts with a photon appropriately to induce cleavage. The positioning of the laser is extremely important to ensure exposure of the stream for a significant period of time. Tuning the laser to a specific frequency allows for precise control over the bonds that are induced to cleave. Thus mass labels linked with an appropriate photocleavable linker to their probes can be readily cleaved within the mass spectrometer. The photocleavage stage does not require a tandem geometry, the photocleavage chamber could be within or immediately following the ion source.

A further technique is surface induced decomposition. Surface induced decomposition is another tandem analyser technique that involves generating an ion stream which is passed through the first analyser. This stream is then collided with a solid surface at a glancing angle. The collision fragments can then be analysed by a second separator and detector configuration.

Induced cleavage can be performed in geometries other than tandem analysers. Ion traps mass spectrometers can promote fragmentation through introduction of a gas into the trap itself with which trapped ions will collide. Ion traps generally contain a bath gas, such as helium but addition of neon for example, promotes fragmentation. Similarly photon induced fragmentation could be applied to trapped ions.

Mass Label Chemistries:

For any practically or commercially useful system it is important that construction of labels be as simple as possible using as few reagents and processing steps as possible. A combinatorial approach in which a series of monomeric molecular units are available to be used in multiple combinations with each other

would be ideal.

One can synthesise mass labels using standard organic chemistry techniques. Such labels ought to carry a single charge bearing group and should be resistant to fragmentation in the mass spectrometry technique used. Amine derivatives, quaternary ammonium ions or positive sulphur centres are good charge carriers if positive ion mass spectrometry is used. These have extremely good detection properties that generate clean sharp signals. Similarly, negatively charged ions can be used, so molecules with carboxylic acid, sulphonic acid and other moieties are appropriate for negative ion spectrometry. Labels for MALDI mass spectrometry can be generated by derivitising known molecules that are excitable by UV laser light, such as sinapinnic acid or cinnamic acid, of which a number of derivatives are already commercially available. Fragmentation resistant groups are discussed above. For a text on organic chemistry see:

◦ Vogel's "Textbook of Organic Chemistry" 4th Edition, Revised by B.S. Furniss, A.J. Hannaford, V. Rogers, P.W.G. Smith & A.R. Tatchell, Longman, 1978.

Amino acids:

With a small number of amino acids such as glycine, alanine and leucine, a large number of small peptides with different masses can be generated using standard peptide synthesis techniques well known in the art. With more amino acids many more labels can be synthesised.

◦ E. Atherton and R.C. Sheppard, editors, 'Solid Phase Peptide Synthesis: A Practical Approach', IRL Press, Oxford.

Carbohydrates:

Similarly carbohydrate molecules are useful monomeric units that can be synthesised into heteropolymers of differing masses but these are not especially amenable to ESMS.

◦ Gait, M.J. editor, 'Oligonucleotide Synthesis: A Practical Approach', IRL Press, Oxford, 1990

◦ Eckstein, editor, 'Oligonucleotides and Analogues: A Practical Approach', IRL Press, Oxford, 1991

Other labelling chemistries:

Clearly almost any molecule can be tacked onto another as a label. Obviously the properties of such labels in the mass spectrometer will vary. In terms of analysing biomolecules it will be important that the labels be inert, bear a single charge and be resistant to fragmentation.

Linkers for cleavage within the mass spectrometer

Compounds having the formula N-L-M are useful in the present invention where cleavage in the mass spectrometer is desired. N comprises one or more nucleic acid bases and would constitute the nucleotide or oligonucleotide probe or primer. L comprises a linker moiety and M comprises a mass marker optionally having a metal ion-binding moiety. The metal ion-binding moiety is a porphyrin, a crown ether, hexahistidine, or a multi-dentate ligand, preferably a bi-dentate ligand or EDTA. The metal ion-binding moiety may be bound to a monovalent, divalent or trivalent metal ion such as a transition metal ion or a metal ion of Group IA, IIA or IIIA of the periodic table. Preferably, the metal ion is Ni^{2+} , Li^{+} , Na^{+} , K^{+} , Mg^{2+} , Ca^{2+} , Sr^{2+} , Ba^{2+} , or Al^{3+} .


The mass marker may comprise a substituted or unsubstituted polyether which may be a substituted or unsubstituted poly(aryl ether). The polyether may comprise one or more fluorine atom

substituents.

L is a group having the formula $-R_1-Si-R_2-$ in which R_1 and R_2 are substituents selected such that when the compound reacts with an electron donating moiety, either N or M cleaves from the Si atom in preference to R_1 and R_2 . R_1 and R_2 are selected such that each has a bond energy to Si greater than the bond energy of N and/or M to Si to ensure that when the compound reacts with an electron donating moiety either N or M cleaves from the Si atom in preference to R_1 and R_2 , and/or R_1 and R_2 are selected such that their steric bulk is sufficient to ensure that when the compound reacts with an electron donating moiety either N or M cleaves from the Si atom in preference to R_1 and R_2 .

More preferably, R_1 and R_2 are independently a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group. More preferably, R_1 and R_2 are each independently fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenyl groups. The electron-donating moiety may be a lewis base such as ammonia, a primary secondary or tertiary amine, a compound containing a hydroxy group, an ether or water.

In one example, L is a group having the formula



- 40 -

in which R is an electron-withdrawing substituent such as a hydrogen atom, halogen atom, or a substituent comprising a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a trifluoroacetyl group, or a trifluoromethyl acetate group. L may be attached to N and/or M by a -CO-NH- group, an -NH-CO-NH- group, an -NH-CS-NH- group, a -CH₂-NH- group, an -SO₂-NH- group, an -NH-CH₂-CH₂- group, or an -OP(=O)(O)O- group.

Quantification and mass spectrometry:

For the most part biochemical and molecular biological assays are quantitative. The mass spectrometer is not a simple device for quantification but use of appropriate instrumentation can lead to great sensitivity. It must always be remembered that the ion count is not a direct measure of the source molecule quantity, the relationship is a complex function of the molecule's ionisation behaviour. Quantitation is effected by scanning the mass spectrum and counting ions at each mass/charge ratio scanned. The count is integrated to give the total count at each point in the spectrum over a given time. These counts can be related back to the original quantities of source molecules in a sample. Methods for relating the ion count or current back to the quantity of source molecule vary. External standards are one approach in which the behaviour of the sample molecules is determined prior to measurement of unknown sample. A calibration curve for each sample molecule can be determined by measuring the ion current for serial dilutions of a sample molecule when fed into the instrument configuration being used.

Internal standards are probably the more favoured approach rather than external standards, since an internal standard is subjected to the same experimental conditions as the sample so any experimental vagaries will affect both internal control and sample molecule. To determine the quantity of a sample molecule, an internal standard of a known quantity is added to the sample. The internal standard is chosen to have a similar ionisation behaviour as the molecule being measured. Thus the ratio of

sample ion count to standard ion count can be used to determine the quantity of sample as the ratio of quantities should be the same. Choosing appropriate standards is the main difficulty with this approach. One must find a molecule that is similar but not identical in its mass spectrum. A favourable approach is to synthesise the sample molecule with appropriate isotopes to give a slightly different mass spectrum, for a molecule with the same chemical behaviour. This approach might be less desirable than external standards for use with large numbers of mass labels due to the added expense of finding or synthesising appropriate internal standards but will give better quantification than external standards. An alternative to isotope labelling is to identify a molecule that has similar but not identical chemical behaviour as the sample in the mass spectrometer. Finding such analogues is difficult and is a significant task for large families of mass labels.

A compromise approach might be appropriate though, since large families of mass labels will ideally be synthesised combinatorially, and will thus be related chemically. A small number of internal controls might be used, where each individual control determines the quantities of a number of mass labels. The precise relationship between internal standard and each mass label might be determined in external calibration experiments to compensate for any differences between them.

The configuration of the instrument is critical to determining the actual ion count itself, particularly the ionisation method and the separation method used. Certain separation methods act as mass filters like the quadrupole which only permits ions with a particular mass charge ratio to pass through at one time. This means that a considerable proportion of sample never reaches the detector. Furthermore most mass spectrometers only detect one part of the mass spectrum at a time. Given that a large proportion of the mass spectrum may be empty or irrelevant but is usually scanned anyway, this means a further large proportion

of the sample is wasted. These factors may be a problem in detecting very low abundance ions but these problems can in large part be overcome by correct configuration of the instrumentation.

To ensure better quantification one could attempt to ensure all ions that are generated are detected. Mattauch-Herzog geometry sector instruments permit this but have a number of limitations. Sector instruments are organised into distinct regions, 'sectors', that perform certain functions. In general the ionisation chamber feeds into a free sector which feeds into an 'electric sector'. The electric sector essentially 'focusses' the ion beam which is divergent after leaving the ion source. The electronic sector also ensures the ion stream has the same energy. This step results in the loss of a certain amount of sample. This focussed ion beam then passes through a second free area into a magnetic sector which splits the beam on the basis of its mass charge ratio. The magnetic sector behaves almost like a prism. A photographic plate can be placed in front of the split beam to measure the intensities of the spectrum at all positions. Unfortunately there is a limit on the dynamic range of these sorts of detector and it is messy and cumbersome. Better dynamic range is achievable with electron multiplier arrays, but at a cost of loss in resolution which is limited by how close together the elements of the array can be constructed. With a family of well characterised mass labels one would probably monitor only sufficient peaks to sample all the mass labels unambiguously. In general array detectors would allow one to simultaneously and continuously monitor a number of regions of the mass spectrum simultaneously, which might be applicable for use with well characterised mass label families. The limit on the resolution of closely spaced regions of the spectrum might restrict the number of labels one might use, though, if array detectors are chosen. For 'selected ion monitoring' (SIM) the quadropole has an advantage over many configurations in that the fields that filter ions can be changed with extreme rapidity allowing a very high sampling rate over a small number of peaks of interest.

Orthogonal TOF mass spectrometry:

An approach that is preferable to array geometries is the orthogonal time of flight mass spectrometer (see Figure 11). This geometry that allows for very fast sampling of an ion stream followed by almost instantaneous detection of all ion species. The ion current leaving the source, probably an electrospray source for many biological applications, passes an electrode plate perpendicular to the current. This plate is essentially an electrical gate and is used to generate a repulsive potential which deflects the ion current 'orthogonally' into a time of flight mass analyser that uses a reflectron. The reflectron is essentially a series of circular electrodes that generate an increasingly repulsive electromagnetic field that normalises ion energies and reflects the ion stream into a detector. The reflectron is a simple device that greatly increases the resolution of TOF analysers. Ions leaving the ion source will have different energies, faster ions will penetrate the repulsive field further than ions with a lower energy and so will be delayed slightly with respect to the lower energy ions but since they will arrive slightly before the lower energy ions they will enter the TOF at roughly the same time so all the ions of a given mass charge ratio will arrive at the detector at roughly the same time. When the electrical gate is 'closed' to deflect ions into the TOF analyser, the timer is triggered. The flight time of the deflected ions is recorded and this is sufficient to determine their mass/charge ratio. The gate generally only sends a short pulse of ions into the TOF analyser at any one time. Since the arrival of all ions is recorded and since the TOF separation is extremely fast, the entire mass spectrum is measured effectively simultaneously. Furthermore, the gate electrode can sample the ion stream at extremely high frequencies so very little sample is required. For these reasons this geometry is extremely sensitive, to the order of a few femtomoles.

Primer Extension and Parallel Sequencing of Subsets of Nucleic Acid Fragments:

Sequencing a single molecule by ligation of single stranded oligonucleotides to a Sanger-like sequence ladder:

Referring to Figure 12, consider a population of copies of a single nucleic acid, immobilised at one terminus to a fixed insoluble matrix. This molecule is rendered single stranded, except for a short stretch of double-stranded DNA at the immobilised terminus of the molecule to serve as a primer for the DNA polymerase reaction. This primer sequence could be provided by the adaptor used to immobilise the terminus or could be a PCR primer if the template is an amplified product. Thus far the technology is as taught by (S. Stahl, T. Hultman, A. Olsson, T. Moks, M. Uhlen, 1988, "Solid Phase DNA sequencing using the biotin-avidin system". Nucleic Acids Research.16, 3025-3038) for solid phase Sanger synthesis. An important feature of this approach is in the blocking nucleotides, which would preferably not be dideoxynucleotides, but rather would be reversibly blocked. This means that after allowing the template to be polymerised in the presence of chain terminating nucleotides, one is left with the expected Sanger ladder of fragments. One can wash away the polymerisation reagents leaving the immobilised Sanger fragments. At this stage the blocking groups are removed to expose a 3' hydroxyl which is amenable to further extension. In the simplest case each terminating base is labelled with a mass label that identifies it uniquely which can be analysed by mass spectrometry as described above, however this does not allow one to really exploit the possibility of analysing a number of heterogenous sequence templates simultaneously. Thus one would prefer to use a removable blocking group whose identity is not determined and which exposes the 3' -OH of the blocked sequence for further extension.

To these exposed termini one can then ligate oligonucleotides of a pre-determined length (N) each bearing a photocleavable mass label that identifies the sequence of the oligonucleotide so that

- 45 -

the next N bases of the sequence 3' of the previously nucleotide are identified by a complementary oligonucleotide bearing a label that identifies its sequence. This is shown in Figure 13. Suitable labelling systems for use with this invention are described herein, as well as in PCT/GB98/00127 of the present applicant. Ligation can be chemical or enzymatic. This stage of the sequencing process will therefore extend each fragment composing the chain terminated population by N bases leaving one with a new ladder of terminated fragments. Mass-labelled oligonucleotides would preferably be added in two sets of 128 such that each member in the first set would have its complement in the other set. This overcomes the problem of cross-hybridisation between complementary 4-mers.

The immobilised matrix can then be washed to remove any unbound oligonucleotides, a water wash would probably be sufficient to disrupt hybridisation. To determine the sequence of the 4 base oligonucleotide that ligated to each Sanger fragment, one need only analyse the label attached to the 3' end of the oligonucleotide. The labelling system for use with this invention is described in PCT/GB98/00127 in which the mass of the label identifies its carrier. Such labels can be made photolabile or cleavable by a specific chemical or biological agent. As detailed in Figure 14, cleavage of the label will release it into solution in which it can be injected into an electrospray mass spectrometer for analysis, which will determine the sequence of the oligonucleotide and furthermore, its quantity. Sample results are shown in Figure 15. Prior to cleavage of labels one needs to separate the Sanger ladder into its component fragment lengths. In a mass spectrometry system this stage can be coupled to the sample loading in a LCMS system. Separation into bands can be achieved by capillary zone electrophoresis. This will then pass through a UV spectrometer to determine the quantity of DNA in each band. Following this the sample will then pass through a photocleavage module to release the mass-labels which will then be injected into an electrospray mass spectrometer for analysis of the labels in each band.

- 46 -

In one embodiment one can probe the immobilised Sanger ladder with every one of the possible 256 single-stranded 4 base oligonucleotides. Each of these would carry a unique identifying label corresponding to its known, sequence of 4 bp. In the 5' to 3' format, the label could be attached to the 3' -OH effectively blocking them from further extension, or a separate blocking group can be used and the label can be attached elsewhere in the molecule.

One could use chemical ligation rather than enzymatically catalysed ligation if that is preferred. This may be advantageous as it would permit probes to be synthesised from DNA analogues not accepted by a ligase such as Peptide Nucleic Acid (PNA) or other analogues. PNA is desirable as it has higher affinity for its complementary DNA sequence than DNA probes.

Other advantages may be that chemical ligation would allow the use of electric fields to regulate the stringency of hybridisation of probes electrostatically.

In a preferred embodiment, a photolysable linker would connect the mass label to the 3'-OH which when cleaved would regenerate the 3'-OH with as high an efficiency as possible. The primer has then been extended by 4 known bases and the cycle can be repeated to determine the next 4 bp of sequence. This process can be repeated iteratively until the entire molecule has been sequenced.

An alternative implementation to using photolysable mass labels at the 3'-OH of each 4-mer oligonucleotide would be to cap the 3'-OH with a phosphate group. One could also use dideoxynucleotides or any other appropriate means to block the 3' -OH of the probe molecules. The mass-label could be attached to another part of the molecule from which it can be released independently of the uncapping reaction of the 3' terminus.

Uncapping of the 3' terminus can be effected by washing the immobilised DNA with alkaline phosphatase which will readily remove the capping phosphate from the 3'-OH leaving it available for the next cycle of the sequencing process.

Conceivably this system could be implemented with other labelling schemes, but most other labelling schemes do not generate sufficient, unique labels to be practical.

Sequencing a Population of Nucleic Acid Fragments:

The same process can be applied to a heterogeneous population of immobilised nucleic acids allowing them to be analysed in parallel. To be successful when applied to a population of nucleic acids, this method relies on the assumption that statistically 1 out of 256 molecules within the total population will carry each of the possible 4 bp sequences adjacent to each terminated Sanger fragment. If one sub-sorts ones nucleic acid population into manageable subsets of less than 256 fragments, one would expect that almost all will have different sequences following each terminating base in the Sanger ladder so for most purposes one can assume that a hybridisation signal corresponds to a single DNA type. This all assumes that DNA sequences are random sequences of bases which is not strictly true but is a sufficient assumption for the purposes of this invention. Obviously 1 in a 1000 is not a small probability and sequences will often have the same 4-mer at the same point in a Sanger ladder.

However this invention includes algorithms that can resolve to a great extent any possible ambiguities caused by this occurrence.

Reconstructing Sequences of Target Nucleic Acids:

Analysis of the labels in each band of the modified Sanger ladder will generate a matrix of quantities of label corresponding to

- 48 -

each possible probe. Shown below is a possible matrix for all probes of 4 base pairs in length:

Sequence to which label corresponds	Cycle 1	Cycle 2	Cycle 3	Cycle 4
AAAA	5	24	13	7
AAAC	10	5	9	13
AAAG	13	9	15	17
.....
TTTG	7	13	17	10
TTTT	17	10	7	14

To reconstruct the sequences to which these quantities of label correspond, this invention also envisions algorithms for analysing such a data matrix. The algorithm attempts to identify a sequence on the basis of its frequency, i.e. a sequence present at a given frequency will have every subsequence present at the same frequency. The algorithm searches through each column of the matrix and attempts to resolve label quantities, that may be sums of sequence frequencies into atomic quantities such that the same set of atomic quantities appear in all columns. The algorithm achieves this by comparing label quantities in a given column with those in all the other columns. A given atomic quantity that appears in all columns is then assumed to correspond to a unique sequence.

If two sequences have the same n-mer at a particular point in the sequence, these can be resolved by the quantitative nature of this system in that the quantity of a particular n-mer in a particular ligation will be the sum of the quantities of the two sequences that share the n-mer at the same point. These can be largely resolved by comparison of one cycle with previous and

subsequent ligation cycles to identify such sums. This is made particularly simple if the sequences that are being analysed have been amplified by PCR such that the sequence in the lowest quantity is present at not less than half the quantity of the sequence with the greatest frequency, that is to say if the frequency range of sequences lies between some quantity N and $2N$. This means that any sum of frequencies will be greater than $2N$ and hence readily detectable.

Notice that if the sequence template is a Sanger Ladder, ligation and identification of 4-mers to such a ladder will provide overlapping 4-mers, thus providing significant redundancy that should provide sufficient information to eliminate most ambiguities that might arise in individual columns of the reconstruction matrix.

Ligase Chain Reaction:

A further embodiment of this invention uses a variant of the Ligase Chain Reaction. A single stranded template is immobilised and then primed at the 3' terminus of the molecule. To this immobilised template is added the 256 possible 4-mers in the presence of a ligase. The 4-mers are phosphorylated at the 5' terminus. For each 4-mer variant a small, predetermined proportion of the probe is present with its 3'-OH blocked with a photocleavable mass label. The 4-mers will hybridise to the template and the ligase will ligate them. However, for any given copy of the template there will be a distinct probability that an irreversibly blocked 4-mer will be incorporated at a given point, thus preventing further extension.

This will generate a ladder of terminated fragments in a manner that is analogous to the Sanger sequencing reaction. The identity of the terminating 4-mers can be determined by separating the terminated fragments by capillary electrophoresis followed directly by analysis of the photocleaved mass labels by

electrospray mass spectrometry.

Here again multiple templates can be analysed simultaneously because of the fact that at any point in the sequence a given 4-mer will occur at a relatively low probability.

This embodiment permits an additional level of multiplexing. This embodiment will give a ladder of fragments where each fragment is N bases longer than the previous fragment where N is the length of the ligation probes used. Capillary electrophoresis will give single base resolution so if the template population is divided into 4 subsets, one can prime each subset with a primer one base longer than the previous primer. This will give 4 populations of fragments resolved from each other by a single base.

Ligation of Sanger Ladders to an array of DNA probes and MALDI detection of fragments:

A further embodiment of the invention uses immobilised probes rather than mass labelled probes in solution. In this embodiment a Sanger Ladder of fragments is generated as described above. The immobilised fragments are then released from the solid phase substrate and ligated to an array of oligonucleotides bearing all 4^N probes of length N at discrete locations on the array surface. The linkers attaching the probes to the array surface would be photocleavable. The array would then be washed and treated with an appropriate exonuclease to trim any single-stranded DNA remaining. The array would be washed again and a suitable MALDI matrix would be applied to the array. The array would be placed in MALDI-TOF spectrometer and each location on the array surface, corresponding to a specific N-mer probe, would be scanned by a laser, first at a frequency to cleave the linker immobilising the probes and then at the frequency required to excite the matrix used. This will ionise the fragments ligated to the surface at the location scanned. These will be detected by Time Of Flight

spectrometry.

For each location on the array one will thus know the sequence of the N bases 3' of the termination point in each fragment, the mass hence length of the fragments ligated and the quantity of each fragment. This will allow the generation of an equivalent data matrix to that for the capillary electrophoresis mass spectrometry embodiment to be generated.

CLAIMS:

1. A method for characterising DNA, which comprises:

- (i) providing a population of DNA fragments, each fragment having cleavably attached thereto a mass label for identifying a feature of that fragment;
- (ii) separating the fragments on the basis of their length;
- (iii) cleaving each fragment in a mass spectrometer to release its mass label; and
- (iv) determining each mass label by mass spectroscopy to relate the feature of each fragment to the length of the fragment.

2. A method according to claim 1, which further comprises:

- (a) providing at least one DNA single-stranded template primed with a primer; and
- (b) generating the population of DNA fragments from the at least one template, wherein the population comprises at least one series of DNA fragments, the or each series containing all possible lengths of a second strand of DNA complementary to the or each template;

wherein the feature of each fragment determined by each mass label relates to a nucleotide or nucleotide sequence at one end of each fragment, so that each nucleotide is related to a position in the template associated with the mass label so as to deduce the sequence of the or each template.

3. A method according to claim 2, wherein the series of DNA fragments is provided by contacting the template in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each

probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, and wherein each fragment is terminated with one of the probes.

4. A method according to claim 2, wherein the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each template in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, wherein each fragment is terminated with one of the probes, and wherein each set of mass labels from each set of four probes associated with each reaction zone is different from the other sets of mass labels; and the fragments are pooled before step (ii).

5. A method according to claim 2, wherein the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each template in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a probe containing only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but

blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein either the primer or the modified nucleotide of the probe is cleavably attached to the mass label, which mass label is associated with the reaction zone and uniquely resolvable in mass spectrometry from the mass label in the other reaction zones for identifying the modified nucleotide used in the reaction zone; and the fragments are pooled before step (ii).

6. A method according to claim 2, wherein the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting the plurality of templates in each of four separate reaction zones in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a probe containing in each of the reaction zones only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein the primer is cleavably attached to the mass label, which mass label is associated with the primer and uniquely resolvable in mass spectrometry from the mass labels associated with the other primers used in the reaction zone; and wherein each nucleotide from its corresponding reaction zone is related to its position in the template.

7. A method according to claim 2, wherein the at least one template is four sets of DNA single-stranded templates, each set comprising an identical plurality of DNA single-stranded templates and the series of DNA fragments is provided by contacting each set in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the templates for forming a second strand of DNA

- 55 -

complementary thereto, wherein the mixture further comprises a probe containing in each of the reaction zones only one of the four nucleotides for hybridising to the template, the nucleotide of which probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto, wherein each fragment is terminated with the probe and wherein each of the templates of the four sets is primed with a primer to which the mass label is cleavably attached, which mass label which uniquely resolvable in mass spectrometry from the mass labels corresponding to the other templates and which is relatable to its respective template and its respective reaction zone, wherein the fragments are pooled before step (ii), and each nucleotide from its corresponding reaction zone is related to its position in the template.

8. A method according to claim 2, wherein the at least one template is a plurality of templates and the series of DNA fragments is provided by contacting each set of templates in a separate reaction zone in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary thereto, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the template in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but blocked to prevent further polymerisation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified nucleotide, wherein each fragment is terminated with one of the probes, and wherein each set of mass labels from each set of four probes associated with each reaction zone is different from the other sets of mass labels and, before step (ii), the fragments are pooled and the pooled fragments are sorted according to a sub-sequence having a common length of 3 to 5 bases adjacent to the primer to form an array of groups of sorted fragments, wherein each group is

spatially separated from the other groups.

9. A method according to claim 2, wherein the series of DNA fragments is provided by

(i) contacting the template in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the templates in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible lengths of the second strand of DNA, each second strand terminated with one of the probes;

(ii) removing unpolymerised nucleotides;

(iii) unblocking the modified nucleotides; and

(iv) contacting the series of templates with an array of oligonucleotide probes, wherein each oligonucleotide probe has a nucleotide sequence of common length 2 to 6, all combinations of sequences are present in the array, and wherein each probe is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the nucleotide sequence.

10. A method according to claim 2, wherein the at least one template is a plurality of primed DNA single-stranded templates, each at a unique concentration, and the series of DNA fragments is provided by

(i) contacting the templates in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the templates, wherein the mixture further comprises a set of four probes containing all four nucleotides

for hybridising to the templates in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible lengths of the second strand of DNA, each second strand terminated with one of the probes;

(ii) removing unpolymerised nucleotides;

(iii) unblocking the modified nucleotides; and

(iv) contacting the series of templates with an array of oligonucleotide probes, wherein each oligonucleotide probe has a nucleotide sequence of common length 2 to 6, all combinations of sequences are present in the array, and wherein each probe is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the nucleotide sequence.

11. A method according to claim 2, wherein the series of DNA fragments is provided by contacting the template in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, and the series of fragments contains all possible lengths of the second strand of DNA of integer multiples of 1, in which each fragment is terminated with one of the probes.

12. A method according to claim 2, wherein the at least one template is a plurality of primed DNA single-stranded templates, each at a unique concentration, and the series of DNA fragments is provided by contacting the templates in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary to the templates, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to the mass label, which mass label is uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, and the series of fragments contains all possible lengths of the second strand of DNA of integer multiples of 1, in which each fragment is terminated with one of the probes.

13. A method according to claim 5 or claim 6, wherein the plurality of single-stranded templates is primed by hybridising to a known sub-sequence common to each of the templates an array of primers each comprising a base sequence containing a common sequence complementary to the known sub-sequence and a variable sequence of common length, in the range 2 to 6, in which the array contains all possible sequences of that common length and the mass label cleavably attached to each primer is relatable to the variable sequence, which variable sequence is relatable to the particular template to be sequenced.

14. A method according to claim 8, wherein the step of sorting the pooled fragments comprises contacting the fragments with an array of spatially separate oligonucleotides each comprising a base sequence containing a common sequence complementary to the primer sequence of the fragments and a

variable sequence of the common length, which array contains all possible variable sequences of the common length.

15. A method according to any one of claims 4 to 7, wherein the reaction zones are separate containers.

16. A method according to any one of claims 3 to 10 or 13 to 15, wherein the mixture of nucleotides comprises ATP, TTP, CTP and GTP.

17. A method according to any one of claims 2 to 10 or 13 to 16, wherein the modified nucleotides are dideoxy- or deoxynucleotides.

18. A method according to any one of claims 2 to 17, wherein the primed DNA is immobilised on a solid support.

19. A method according to any one of the preceding claims, wherein the step of separating the fragments on the basis of their length is effected by capillary electrophoresis.

20. A method according to any one of the preceding claims, wherein each mass label is cleavably attached to a fragment by a linker cleavable in a mass spectrometer.

21. A method for characterising DNA, which comprises

- (a) providing a primed DNA single-stranded template;
- (b) contacting the template in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the templates in which the nucleotide of each probe comprises a

- 60 -

modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible lengths of the second strand of DNA, each second strand terminated with one of the probes;

(c) removing unpolymerised nucleotides;

(d) unblocking the modified nucleotides;

(e) contacting the series of templates with an array of oligonucleotide probes to form a series of fragments, each oligonucleotide probe having a nucleotide sequence of common length 2 to 6, and all combinations of sequences being present in the array, wherein each probe is cleavably attached to a corresponding mass label uniquely resolvable in mass spectrometry for identifying the nucleotide sequence;

(f) separating the fragments from one another on the basis of their length;

(g) cleaving each fragment to release its mass label; and

(h) determining each mass label by mass spectrometry to relate its corresponding nucleotide sequence to a position in the template so as to deduce the sequence of the template.

22. A method for characterising DNA, which comprises

(a) providing a plurality of primed DNA single-stranded templates, each at a unique concentration;

(b) contacting the templates in the presence of DNA polymerase with a mixture of nucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the templates, wherein the mixture further comprises a set of four probes containing all four nucleotides for hybridising to the templates in which the nucleotide of each probe comprises a modified nucleotide which is capable of polymerising to the second strand of DNA but reversibly blocked to prevent further polymerisation thereto, wherein the step of contacting forms a series of templates containing all possible

- 61 -

lengths of the second strand of DNA, each second strand terminated with one of the probes;

(c) removing unpolymerised nucleotides;

(d) unblocking the modified nucleotides;

(e) contacting the series of templates with an array of oligonucleotide probes to form a series of fragments, each oligonucleotide probe having a nucleotide sequence of common length 2 to 6, and all combinations of sequences being present in the array, wherein each probe is cleavably attached to a corresponding mass label uniquely resolvable in mass spectrometry for identifying the nucleotide sequence;

(f) separating the fragments from one another on the basis of their length;

(g) cleaving each fragment to release its mass label; and

(h) determining the identity and amount of each mass label by mass spectrometry to relate its corresponding nucleotide sequence to a position in its respective template so as to deduce the sequence of the template.

23. A method for characterising DNA, which comprises

(a) providing a primed DNA single-stranded template;

(b) contacting the template in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the template for forming a second strand of DNA complementary to the template, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to a corresponding mass label uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, wherein the step of contacting forms a series of fragments containing all possible lengths of the second strand

- 62 -

of DNA of integer multiples of 1, each fragment terminated with one of the probes;

(c) separating the fragments from one another on the basis of their length;

(d) cleaving each fragment to release its mass label; and

(e) determining each mass label by mass spectrometry to relate its corresponding oligonucleotide to a position in the template so as to deduce the sequence of the template.

24. A method for characterising DNA, which comprises

(a) providing a plurality of primed DNA single-stranded templates, each at a unique concentration;

(b) contacting the templates in the presence of DNA ligase with a mixture of oligonucleotides sufficient for hybridising to the templates for forming a second strand of DNA complementary to the templates, the oligonucleotides each having a common length in the range 2 to 6, wherein the mixture further comprises a set of probes containing all possible oligonucleotides of the common length 1 for hybridising to the templates in which the oligonucleotide of each probe comprises a modified oligonucleotide which is capable of ligating to the second strand of DNA but blocked to prevent further ligation thereto and which is cleavably attached to a corresponding mass label uniquely resolvable in mass spectrometry for identifying the modified oligonucleotide, wherein the step of contacting forms a series of fragments containing all possible lengths of the second strand of DNA of integer multiples of 1, each fragment terminated with one of the probes;

(c) separating the fragments from one another on the basis of their length;

(d) cleaving each fragment to release its mass label; and

(e) determining the identity and amount of each mass label by mass spectrometry to relate its corresponding oligonucleotide to a position in its respective template so as to deduce the sequence of the template.

25. Use of a probe or a set of probes in a method according to any one of claims 1 to 22, wherein each probe comprises a modified nucleotide or oligonucleotide which is capable of polymerising to a second strand of DNA complementary to the template but blocked to prevent further polymerisation thereto, which modified nucleotide or oligonucleotide is cleavably attached to a mass label for identifying the modified nucleotide, and wherein each mass label is cleavable from the probe in a mass spectrometer, is resolvable by mass spectrometry and is relatable to its corresponding modified nucleotide or oligonucleotide.

26. Use of a set of oligonucleotide primers in a method according to any one of claims 1, 2, 5, 6, 7 or 13, each primer of which comprises a mass label cleavably attached to an oligonucleotide primer base sequence for hybridising to a DNA single-stranded template to form a primed template, wherein each mass label of the set, is cleavable from the primer in a mass spectrometer, is uniquely resolvable in relation to every other mass label in the set by mass spectrometry and is relatable to the oligonucleotide primer base sequence.




FIG. 1






FIG. 2



S - STREPTAVIDIN COATED BEAD OR WELL
B - BIOTIN
X - PRIMER X SEQUENCE
Y - PRIMER Y SEQUENCE

FIG. 3



5 / 14






FIG. 4b




FIG. 5

7 / 14




FIG. 6




FIG. 7




FIG. 8

9 / 14




FIG. 9





FIG. 10



ORTHOGONAL TOF GEOMETRY

FIG. 11

11 / 14




FIG. 12

12 / 14






FIG. 13

13 / 14



14 / 14

BANDS						
1	C	C	A	A		
2		C	A	A	C	
3			A	A	C	T
FINAL	C	C	A	A	C	T

FIG. 15

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/GB 98/02048

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB) 9 February 1995 see claims and figures ---	1-26
Y	US 5 302 509 A (CHEESEMAN PETER C) 12 April 1994 see the whole document ---	1-26
A	WO 96 32504 A (UNIV BOSTON) 17 October 1996 ---	1-26
A	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 see the whole document ---	1-26
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/GB 98/02048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 97 27331 A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 see whole document,esp examples and claims -----</p>	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504160 A	09-02-1995	AT 159767 T AU 695349 B AU 7269194 A CA 2168010 A CN 1131440 A DE 69406544 D DE 69406544 T DK 711362 T EP 0711362 A EP 0778280 A ES 2108479 T FI 960403 A HU 73802 A JP 9501830 T NO 960370 A US 5770367 A	15-11-1997 13-08-1998 28-02-1995 09-02-1995 18-09-1996 04-12-1997 26-02-1998 22-12-1997 15-05-1996 11-06-1997 16-12-1997 29-01-1996 30-09-1996 25-02-1997 28-03-1996 23-06-1998
US 5302509 A	12-04-1994	NONE	
WO 9632504 A	17-10-1996	AU 5544696 A CA 2218188 A EP 0830460 A	30-10-1996 17-10-1996 25-03-1998
WO 9633205 A	24-10-1996	US 5750341 A AU 5549096 A CA 2218017 A EP 0871646 A	12-05-1998 07-11-1996 24-10-1996 21-10-1998
WO 9727331 A	31-07-1997	AU 2247397 A EP 0868535 A	20-08-1997 07-10-1998



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:

C12Q 1/68

A1

(11) International Publication Number:

WO 99/02728

(43) International Publication Date:

21 January 1999 (21.01.99)

(21) International Application Number: PCT/GB98/02048

(22) International Filing Date: 13 July 1998 (13.07.98)

(30) Priority Data:

9714717.7	11 July 1997 (11.07.97)	GB
9714715.1	11 July 1997 (11.07.97)	GB
9719284.3	10 September 1997 (10.09.97)	GB

(71) Applicant (for all designated States except US): BRAX GENOMICS LIMITED [GB/GB]; 13 Station Road, Cambridge CB1 2JB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHMIDT, Günter [DE/GB]; Houghton Manor, Houghton, Cambs PE17 2BQ (GB). THOMPSON, Andrew, Hugin [GB/GB]; 25 Knoll Park, Alloway, Ayr KA7 4RH (GB).





(74) Agents: DANIELS, Jeffrey, Nicholas et al.; Page White & Farrer, 54 Doughty Street, London WC1N 2LS (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: CHARACTERISING NUCLEIC ACIDS



(57) Abstract

A method for characterising DNA, which comprises: (i) providing a population of DNA fragments, each fragment having cleavably attached thereto a mass label for identifying a feature of that fragment; (ii) separating the fragments on the basis of their length; (iii) cleaving each fragment in a mass spectrometer to release its mass label; and (iv) determining each mass label by mass spectroscopy to relate the feature of each fragment to the length of the fragment.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						